L4 ANSWER 8 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1988:183063 CAPLUS
DOCUMENT NUMBER: 108:183063
TITLE: Fast atom bombardment and tandem mass spectrometry for structure determination: remote site fragmentation of steroid conjugates and bile salts
AUTHOR(S): Tomer, K. B.; Gross, M. L.
CORPORATE SOURCE: Midwest Cent. Mass Spectrom., Univ. Nebraska, Lincoln, NE, 68588-0362, USA
SOURCE: Biomed. Environ. Mass Spectrom. (1988), 15(2), 89-98
CODEN: BEMSEN; ISSN: 0887-6134
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of 35 steroid conjugates (sulfates and glucuronides) and bile salts were investigated by using fast atom bombardment and tandem mass spectrometry. Collisional activation of the [M-H]- anions of sulfate conjugates and bile salts predominantly yields fragment ions arising by reactions occurring remote from the charge site. These reactions are sometimes sensitive to differences in stereochem. at positions remote from the charge site and are useful for positional isomer differentiation. On the other hand, collisional activation of the [M-H]- anions of the glucuronide conjugates leads primarily to charge-driven fragmentations.
IT 56162-42-6
RL: PRP (Properties)
(structure of, detn. of, by fast-atom-bombardment and tandem mass spectrometry)
RN 56162-42-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1986:443183 CAPLUS
DOCUMENT NUMBER: 105:43183
TITLE: Chemical conversion of corticosteroids to 3.alpha.,5.alpha.-tetrahydro derivatives. Synthesis of allotetrahydro-11-deoxycortisol glucuronides
AUTHOR(S): Hosoda, Hiroshi; Takasaki, Wataru; Miura, Hiroya; Tohkin, Masahiro; Maruyama, Yuko; Nambara, Toshio
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SOURCE: Chem. Pharm. Bull. (1985), 33(10), 4281-7
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 105:43183
AB A method for the conversion of 11-deoxycortisol into 3.alpha.-hydroxy-5.alpha.-pregnanones is described. The allotetrahydro-11-deoxycortisol monoacetates I (R = H, R1 = Ac; R = Ac, R1 = H), which are key intermediates in the prepn. of the 3- or 21-glucuronide of allotetrahydro-11-deoxycortisol, were the target compds. 5.alpha.-Dihydro-11-deoxycortisol 21-acetate was prepd. by hydrogenation of the 3-ethoxy-3,5-diene II, followed by acid hydrolysis. When the pregnanones III (R1 = tetrahydropyranyl, Me3CSiMe2) were treated with potassium tri-sec-butylborohydride in THF under mild conditions, selective redn. of the carbonyl group at C-3 took place, yielding the 3.alpha.-alcs. IV. Allotetrahydro-11-deoxycortisol 3-glucuronide V (R1 = H) and allotetrahydro-11-deoxycortisol 21-glucuronide VI were then prepd. via Koenigs-Knorr glycosidations.
IT 103292-99-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acetylation of)
RN 103292-99-5 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
IT 103293-04-5P 103293-07-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis of)
RN 103293-04-5 CAPLUS
CN Pregnan-20-one, 3-(acetyloxy)-17-hydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 103293-07-8 CAPLUS
CN Pregnan-20-one, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-17-hydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 103293-12-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sapon. of)
RN 103293-12-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.alpha.)-3-(acetyloxy)-17-

USPT

US-PAT-NO: 3969345
DOCUMENT-IDENTIFIER: US 3969345 A
TITLE: 20.beta.,21-Epoxy-3.alpha.-hydroxy-5.alpha.-pregnanes and derivatives
thereof
DATE-ISSUED: July 13, 1976
INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Phillipps; Gordon	Wembley	N/A	N/A	EN
Hanley	London	N/A	N/A	EN
Newall; Christopher Earle				

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Glaxo Laboratories Limited	Greenford	N/A	N/A	EN	03

APPL-NO: 5/ 551315
DATE FILED: February 20, 1975
PARENT-CASE:
This application is a division of application Ser. No. 208,961, filed Dec.
16, 1971, and now U.S. Pat. No. 3,882,151.
FOREIGN-APPL-PRIORITY-DATA:
FOREIGN-PRIORITY:
FOREIGN-PRIORITY-APPL-NO: UK 60065/70
FOREIGN-PRIORITY-APPL-DATE: December 17, 1970
INT-CL: [2] C07J005/00
US-CL-ISSUED: 260/239.55R,260/397.45 ,260/397.47 ,424/243 ,260/239.5
US-CL-CURRENT: 540/94,514/816 ,540/112 ,552/523 ,552/560 ,552/582 ,552/587
,552/589 ,552/591 ,552/600 ,552/603 ,552/604 ,552/609
FIELD-OF-SEARCH: 260/239.55R

REF-CITED:

U.S. PATENT DOCUMENTS

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
3822298	July 1974	Clayton et al.	260/397.4

ART-UNIT: 124
PRIMARY-EXAMINER: Roberts; Elbert L.
ATTY-AGENT-FIRM: Bacon & Thomas
ABSTRACT:
The invention provides 3.alpha.-oxygenated pregnane 21-ethers possessing a

hydroxy group in the 3.alpha.-position; a hydrogen atom or a methyl group at
the 10-position; a hydrogen atom in the 17.alpha.-position; a keto group in the
20-position; and an etherified hydroxyl group in the 21-position.

4 Claims, 0 Drawing figures

USPT

US-PAT-NO: 3822298
DOCUMENT-IDENTIFIER: US 3822298 A
TITLE: TEXT NOT AVAILABLE
DATE-ISSUED: July 2, 1974
US-CL-ISSUED: 552/609,540/94
US-CL-CURRENT: 552/609,540/100 ,540/111 ,540/94 ,552/529 ,552/560
,552/582
,552/586 ,552/587 ,552/589 ,552/590 ,552/591 ,552/599 ,552/600
,552/603
,552/604

Claims, 0 Drawing figures

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1973:30134 CAPLUS
DOCUMENT NUMBER: 78:30134
TITLE: Glucosiduronates of 3.alpha.,21-dihydroxy-5.beta.-pregnane-11,20-dione. Synthesis of C-3, C-21, and C-3, 21 derivatives
AUTHOR(S): Mattox, Vernon R.; Vrieze, Wiley D.
CORPORATE SOURCE: Mayo Clin. and Mayo Found., Rochester, Minn., USA
SOURCE: J. Org. Chem. (1972), 37(25), 3990-6
CODEN: JOCEAH
DOCUMENT TYPE: Journal
LANGUAGE: English
AB C-3, C-21, and C-3, 21 glucosiduronates of 3.alpha.,21-dihydroxy-5.beta.-pregnane-11,20-dione were prepd.
IT 36707-52-5P 36707-53-6P 36707-54-7P 36707-55-8P 36707-56-9P 36707-58-1P 36707-59-2P 36707-60-5P 36707-61-6P 36707-63-8P 36763-75-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 36707-52-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-dioxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)



RN 36707-53-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-(acetyloxy)-11,20-dioxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-54-7 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-dioxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)



RN 36707-55-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-56-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-dioxopregnan-21-yl, monoammonium salt (9CI) (CA INDEX NAME)



RN 36707-58-1 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis-, dimethyl ester, hexaacetate (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-59-2 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 36707-60-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-

L4 ANSWER 19 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1976:478264 CAPLUS
DOCUMENT NUMBER: 85:78264
TITLE: 21-Substituted pregnanes
INVENTOR(S): Phillipps, Gordon H.; Lawrence, Robin; Newall, Christopher E.; Wright, Michael
PATENT ASSIGNEE(S): Glaxo Laboratories Ltd., Engl.
SOURCE: Brit., 21 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1432135	A	19760414	GB 1972-21145	19730504
BE 799103	A1	19731105	BE 1973-130750	19730504
NL 7306233	A	19731107	NL 1973-6233	19730504
DE 2322560	A1	19731115	DE 1973-2322560	19730504
FR 2183794	A1	19731221	FR 1973-16111	19730504
ZA 7303036	A	19740424	ZA 1973-3036	19730504
JP 49047361	A2	19740508	JP 1973-50184	19730504
AU 7355285	A1	19741107	AU 1973-55285	19730504
US 3959260	A	19760525	US 1974-488989	19740716

PRIORITY APPLN. INFO.: GB 1972-21145 19720505
US 1973-356097 19730501

AB Forty title compds. I (R = H, Me, alkoxy; R1, R2 = H, Me; R32 = O, R3 = H; R4 = acylthio, heterocycle-substituted acylthio, alkylthio, heterocycle-substituted alkylthio, EtSO2, EtSO, NCS, HS, BuS2CS, morpholinocarbodithio, morpholinoethoxythiocarbonylthio) and 2 related compds., useful as anesthetics, were prepd. from 21-bromo steroids by condensation reactions. Thus, refluxing 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione with BzSNa in Me2CO 40 min gave I (R = R1 = H, R2 = Me, R32 = O, R4 = BzS). Solns. of I in aq. nonionic surfactants are suitable for parenteral administration, as is a similar soln. of 21-acetylthio-3.alpha.-hydroxy-5.beta.-pregnane-11,20-dione.

IT 51087-29-7P 51087-32-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(anesthetic, prepn. of)

RN 51087-29-7 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 19 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 51087-32-2 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1976:443170 CAPLUS
DOCUMENT NUMBER: 85:43170
TITLE: Liquid ion exchangers in reversed-phase systems for chromatography of steroidal glucosiduronic acids
AUTHOR(S): Mattox, Vernon R.; Litwiller, Robert D.; Goodrich, June E.; Tan, W. C.
CORPORATE SOURCE: Mayo Clin. and Mayo Grad. Sch., Rochester, Minn., USA
SOURCE: J. Chromatogr. (1976), 120(2), 435-47
CODEN: JOCRAM
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Steroidal glucosiduronic acids were chromatographed on paper by the reversed-phase technique using 5 different liq. ion-exchangers as stationary phase and aq. KCl as mobile phase. The relation of mobility of the acids (RM) to both the amt. of exchanger on the paper and the concn. of KCl in the mobile phase is discussed: the relation may be expressed as RM = n.cntdot.log [exchanger] + const. and RM = -n.cntdot.log [KCl] + const., resp. Migration of the acids in the presence of different exchangers is correlated by use of the equation RM (exchanger Y) = a .times. RM (exchanger X) + b. The lack of appreciable correlation between migration of the acids in a reversed-phase system and a corresponding straight-phase system is discussed and expressed by means of regression equations. The correlation coeffs. and std. errors of est. from these equations provide useful indices for selecting 2 solvent systems that are to be used sequentially to obtain max. resoln. of a group of compds. .DELTA.RM values obtained for various functional groups with reversed-phase and straight-phase techniques are compared.

IT 36707-55-8 36707-60-5 56162-37-9
56162-38-0 56162-41-5 56162-42-6
56162-45-9 56316-33-7 56316-34-8
RL: ANT (Analyte); ANST (Analytical study)
(chromatog. of, by ion-exchange paper)

RN 36707-55-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-60-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 56162-37-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1999:450892 CAPLUS
DOCUMENT NUMBER: 131:102428
TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: U.S., 28 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606

PRIORITY APPLN. INFO.: US 1995-467404 19950606
OTHER SOURCE(S): MARPAT 131:102428
AB Neuroactive steroids of formula I [R = H, NH2, thio, sulfinyl, sulfonyl, halo, alkoxy, alkyl, alkenyl, alkynyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, etc.; R2 = H, alkoxy, keto, Me2N; R3 = alkoxy, alkenyloxy, alkynyloxy; R4 = H, Me; R5 = H, absent; R6 = H, alkanoyl, etc.; R7 = H, halo, OH, alkoxy, etc.; R8 = H, halo; R9 = H, halo, alkyl, alkoxy, arylalkoxy, amino; R10 = H, halo, alkyl, OH, alkoxy, CN, etc.] are prepd. These derivs. are capable of acting at a recently identified site on the GABA receptor complex (GRC), thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.beta.-methoxy-5.beta.-androstan-3-one to give II. II protected 87.5% of mice injected with metrazol from convulsions.
IT **186264-24-4P 186264-34-6P 186264-35-7P 186264-63-1P 186264-79-9P 186264-86-8P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neuroactive steroids of androstane and pregnane series)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)
RN 186264-24-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-35-7 CAPLUS
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1998:112239 CAPLUS
DOCUMENT NUMBER: 128:188632
TITLE: Use of GABA agonists and NMDA receptor antagonists for the treatment of migraine headache
INVENTOR(S): Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA; Lan, Nancy C.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805337	A1	19980212	WO 1997-US13430	19970731
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9739672	A1	19980225	AU 1997-39672	19970731
PRIORITY APPLN. INFO.:			US 1996-22937	19960801
			WO 1997-US13430	19970731

AB Methods are disclosed for treating or preventing migraine headache by administering to an animal a GABA receptor agonist (e.g. a neuroactive steroid) and/or an NMDA receptor antagonist (e.g. a dihydroquinoxaline deriv.). Also disclosed are pharmaceutical compns. and kits for the treatment or prevention of migraine headache.

IT **186264-24-4 186264-34-6 186264-35-7**
186264-63-1 186264-79-9 186264-86-8
203785-83-5
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA agonists and NMDA receptor antagonists for migraine headache treatment)

RN 186264-24-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-35-7 CAPLUS
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 203785-83-5 CAPLUS
CN Pregnan-20-one, 21-(1H-benzimidazol-2-ylthio)-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:113460 CAPLUS
DOCUMENT NUMBER: 126:131695
TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2223996	AA	19961219	CA 1996-2223996	19960606
AU 9661725	A1	19961230	AU 1996-61725	19960606
EP 837874	A2	19980429	EP 1996-919372	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1190404	A	19980812	CN 1996-195360	19960606
BR 9608592	A	19990629	BR 1996-8592	19960606
JP 11507643	T2	19990706	JP 1996-502210	19960606
NO 9705608	A	19980206	NO 1997-5608	19971204
FI 9704448	A	19971205	FI 1997-4448	19971205
PRIORITY APPLN. INFO.:			US 1995-467404	19950606
			WO 1996-US10115	19960606

OTHER SOURCE(S): MARPAT 126:131695

AB Compds. of formula I (R = H, NH2, thio, sulfinyl, sulfonyl, halogen, alkoxy, alkyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.; R2 = H, OH, alkoxy, alkanoyloxy, carbalkoxy, keto, amino; R3 = H, alkoxy, alkenyloxy, etc.; R4 = H, alkyl; R5 = H, absent; R6 = H, alkanoyl, aminocarbonyl, alkoxycarbonyl; R7 = H, halogen, OH, alkoxy, alkanoyloxy, carbalkoxy; R8 = H, halogen; R9 = H, halogen, alkyl, alkoxy, arylalkoxy,

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)

amino; R10 = H, halogen, OH, alkyl, etc.] are prepd. as neuroactive prodrugs, due to their ability to modulate the GABAA receptor-chloride ionophore complex. These derivs. are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.beta.-methoxy-5.beta.-androstan-3-one to give II. II (10 mg/kg IP) protected 87.5% of mice injected with metrazol from convulsions.

IT **186264-24-4P 186264-34-6P 186264-35-7P**
186264-63-1P 186264-79-9P 186264-86-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neuroactive androstanes and pregnanes)

RN 186264-24-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-35-7 CAPLUS
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



● I⁻

```
=> d his


     (FILE 'HOME' ENTERED AT 12:20:12 ON 18 NOV 1999)

     FILE 'REGISTRY' ENTERED AT 12:20:24 ON 18 NOV 1999
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            7 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 12:21:23 ON 18 NOV 1999
L4            3 S L3

     FILE 'BEILSTEIN' ENTERED AT 12:22:28 ON 18 NOV 1999
L5            0 S L1 FULL

     FILE 'MARPAT' ENTERED AT 12:23:18 ON 18 NOV 1999
L6            0 S L3

=> log y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.30     132.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -1.61

STN INTERNATIONAL LOGOFF AT 12:24:03 ON 18 NOV 1999
```

=> d ibib ab hitstr 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1999:450892 CAPLUS
DOCUMENT NUMBER: 131:102428
TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: U.S., 28 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606

PRIORITY APPLN. INFO.: US 1995-467404 19950606
OTHER SOURCE(S): MARPAT 131:102428

AB Neuroactive steroids of formula I [R = H, NH2, thio, sulfinyl, sulfonyl, halo, alkoxy, alkyl, alkenyl, alkynyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, etc.; R2 = H, alkoxy, keto, Me2N; R3 = alkoxy, alkenyloxy, alkynyloxy; R4 = H, Me; R5 = H, absent; R6 = H, alkanoyl, etc.; R7 = H, halo, OH, alkoxy, etc.; R8 = H, halo; R9 = H, halo, alkyl, alkoxy, arylalkoxy, amino; R10 = H, halo, alkyl, OH, alkoxy, CN, etc.] are prepd. These derivs. are capable of acting at a recently identified site on the GABA receptor complex (GRC), thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.beta.-methoxy-5.beta.-androstan-3-one to give II. II protected 87.5% of mice injected with metrazol from convulsions.

IT **186264-24-4P 186264-34-6P 186264-35-7P**
186264-63-1P 186264-79-9P 186264-86-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neuroactive steroids of androstane and pregnane series)



L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)

RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)

RN 186264-24-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-35-7 CAPLUS
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1998:112239 CAPLUS
DOCUMENT NUMBER: 128:188632
TITLE: Use of GABA agonists and NMDA receptor antagonists for the treatment of migraine headache
INVENTOR(S): Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA; Lan, Nancy C.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805337	A1	19980212	WO 1997-US13430	19970731
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9739672	A1	19980225	AU 1997-39672	19970731
PRIORITY APPLN. INFO.:			US 1996-22937	19960801
			WO 1997-US13430	19970731

AB Methods are disclosed for treating or preventing migraine headache by administering to an animal a GABA receptor agonist (e.g. a neuroactive steroid) and/or an NMDA receptor antagonist (e.g. a dihydroquinoxaline deriv.). Also disclosed are pharmaceutical compns. and kits for the treatment or prevention of migraine headache.

IT **186264-24-4 186264-34-6 186264-35-7 186264-63-1 186264-79-9 186264-86-8 203785-83-5**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA agonists and NMDA receptor antagonists for migraine headache treatment)

RN 186264-24-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-35-7 CAPLUS
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 203785-83-5 CAPLUS
CN Pregnan-20-one, 21-(1H-benzimidazol-2-ylthio)-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:113460 CAPLUS
DOCUMENT NUMBER: 126:131695
TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2223996	AA	19961219	CA 1996-2223996	19960606
AU 9661725	A1	19961230	AU 1996-61725	19960606
EP 837874	A2	19980429	EP 1996-919372	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1190404	A	19980812	CN 1996-195360	19960606
BR 9608592	A	19990629	BR 1996-8592	19960606
JP 11507643	T2	19990706	JP 1996-502210	19960606
NO 9705608	A	19980206	NO 1997-5608	19971204
FI 9704448	A	19971205	FI 1997-4448	19971205
PRIORITY APPLN. INFO.:			US 1995-467404	19950606
			WO 1996-US10115	19960606

OTHER SOURCE(S): MARPAT 126:131695

AB Compds. of formula I [R = H, NH2, thio, sulfinyl, sulfonyl, halogen, alkoxy, alkyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.; R2 = H, OH, alkoxy, alkanoyloxy, carbalkoxy, keto, amino; R3 = H, alkoxy, alkenyloxy, etc.; R4 = H, alkyl; R5 = H, absent; R6 = H, alkanoyl, aminocarbonyl, alkoxycarbonyl; R7 = H, halogen, OH, alkoxy, alkanoyloxy, carbalkoxy; R8 = H, halogen; R9 = H, halogen, alkyl, alkoxy, arylalkoxy,

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)

amino; R10 = H, halogen, OH, alkyl, etc.] are prepd. as neuroactive prodrugs, due to their ability to modulate the GABAA receptor-chloride ionophore complex. These derivs. are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.beta.-methoxy-5.beta.-androstan-3-one to give II. II (10 mg/kg IP) protected 87.5% of mice injected with metrazol from convulsions.

IT **186264-24-4P 186264-34-6P 186264-35-7P**
186264-63-1P 186264-79-9P 186264-86-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neuroactive androstanes and pregnanes)

RN 186264-24-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-35-7 CAPLUS
CN 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



● I⁻

=> d ibib ab fqhit

L6 ANSWER 1 OF 1 MARPAT COPYRIGHT 1999 ACS
ACCESSION NUMBER: 122:291311 MARPAT
TITLE: Preparation and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics
INVENTOR(S): Gee, Kelvin W.; Lan, Nancy Tsai-Yun
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427608	A1	19941208	WO 1994-US5820	19940524
W: AU, CA, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2163748	AA	19941208	CA 1994-2163748	19940523
JP 08511771	T2	19961210	JP 1994-500892	19940523
AU 9469883	A1	19941220	AU 1994-69883	19940524
EP 701444	A1	19960320	EP 1994-918659	19940524
R: DE, FR, GB				
US 5939545	A	19990817	US 1997-887229	19970702

PRIORITY APPLN. INFO.:
US 1993-68378 19930524
US 1994-196919 19940214
US 1994-196972 19940214
US 1994-246275 19940519
WO 1994-US5820 19940523
US 1994-346927 19941123
US 1995-389820 19950214

AB Title compds. [e.g.I; R = H, (halo)alkyl, alkenyl, alkynyl, aryl(alkyl), etc.; R1 = H or Me; R2 = cyano, CH2OH, COMe, C.tplbond.CH, etc.; R3 = H; R2R3 = CH2, CHOMe, CHMe, CHEt], for interaction with the GABAA receptor complex to induce sleep in humans, were prepd. Thus, 5.alpha.-pregnane-3,20-dione 20-ketal was converted in 2 steps to title compd. II (R = C.tplbond.CH) which was condensed with 4-IC6H4COMe to give II [R = 4-(MeCO)C6H4C.tplbond.C] which had IC50 of 5nM against TBPS binding at rat cerebral cortex prepn. in vitro.

MSTR 1

L6 ANSWER 1 OF 1 MARPAT COPYRIGHT 1999 ACS (Continued)



G1 = cycloalkyl<(3-8)> (SO (1-) G7)
G4 = 25



G6 = 56

DER: and pharmaceutically acceptable esters
MPL: claim 1

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



● I⁻

RN 186264-87-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 4 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1995:858705 CAPLUS
DOCUMENT NUMBER: 123:266118
TITLE: Codrugs as a method of controlled drug delivery
INVENTOR(S): Ashton, Paul; Crooks, Peter Anthony; Riggs, Robert Mack; Cynkowski, Tadeusz; Cynkowska, Grazyna
PATENT ASSIGNEE(S): University of Kentucky Research Foundation, USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9520567	A1	19950803	WO 1994-US1659	19940217
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2182228	AA	19950803	CA 1994-2182228	19940217
AU 9462545	A1	19950815	AU 1994-62545	19940217
AU 705226	B2	19990520		
EP 740650	A1	19961106	EP 1994-909643	19940217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09509151	T2	19970916	JP 1994-520023	19940217
PRIORITY APPLN. INFO.:			US 1994-187462	19940128
			WO 1994-US1659	19940217

AB A codrug compn. of at least two drug compds. covalently linked to one another via a labile bond to form a single codrug compn., and methods of use of the codrug for the treatment of various medical conditions are disclosed. The codrug may be administered by itself or as a bioerodible or nonbioerodible dosage form, such as injection, liposome, suspension, microsphere, nanoparticle, ointment, transdermal patch, etc.
IT 169046-79-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological Study); PREP (Preparation); USES (Uses)
(codrug compns. for controlled drug delivery)
RN 169046-79-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[[(3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1995:538364 CAPLUS
DOCUMENT NUMBER: 122:291311
TITLE: Preparation and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics
INVENTOR(S): Gee, Kelvin W.; Lan, Nancy Tsai-Yun
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427608	A1	19941208	WO 1994-US5820	19940524
W: AU, CA, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2163748	AA	19941208	CA 1994-2163748	19940523
JP 08511771	T2	19961210	JP 1994-500892	19940523
AU 9469883	A1	19941220	AU 1994-69883	19940524
EP 701444	A1	19960320	EP 1994-918659	19940524
R: DE, FR, GB				
US 5939545	A	19990817	US 1997-887229	19970702
PRIORITY APPLN. INFO.:			US 1993-68378	19930524
			US 1994-196919	19940214
			US 1994-196972	19940214
			US 1994-246275	19940519
			WO 1994-US5820	19940523
			US 1994-346927	19941123
			US 1995-389820	19950214

OTHER SOURCE(S): MARPAT 122:291311
AB Title compds. [e.g.I; R = H, (halo)alkyl, alkenyl, alkynyl, aryl(alkyl), etc.; R1 = H or Me; R2 = cyano, CH2OH, COMe, C.tplbond.CH, etc.; R3 = H; R2R3 = CH2, CHOMe, CHMe, CHEt], for interaction with the GABAA receptor complex to induce sleep in humans, were prepd. Thus, 5.alpha.-pregnane-3,20-dione 20-ketal was converted in 2 steps to title compd. II (R = C.tplbond.CH) which was condensed with 4-IC6H4COMe to give II [R = 4-(MeCO)C6H4C.tplbond.C] which had IC50 of 5nM against TBPS binding at rat cerebral cortex prepn. in vitro.
IT 162883-05-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)
RN 162883-05-8 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI)

L4 ANSWER 5 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1995:274566 CAPLUS
DOCUMENT NUMBER: 122:101622
TITLE: Glycosides of 19-formylthevetiogenin and 5.alpha.-thevetiogenin from Thevetia neriifolia
AUTHOR(S): Abe, Fumiko; Yamauchi, Tatsuo; Yahara, Shoji; Nohara, Toshihiro
CORPORATE SOURCE: Fac. Pharmaceutical Sci., Fukuoka Univ., Fukuoka, 814-01, Japan
SOURCE: Phytochemistry (1994), 37(5), 1429-32
CODEN: PYTCAS; ISSN: 0031-9422
DOCUMENT TYPE: Journal
LANGUAGE: English
AB C-nor-D-homo-homologs of cannogenin and uzarigenin glycosides were isolated along with known cardenolide glycosides from the frozen fresh leaves of Thevetia neriifolia. A bisdesmosidic tetraoside of 3.beta.,14,21-trihydroxy-5.beta.,14.beta.-pregnan-20-one was also obtained from the polar fraction and the structure established.
IT 160625-67-2P
RL: BOC (Biological occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(glycosides of 19-formylthevetiogenin and 5.alpha.-thevetiogenin from Thevetia neriifolia)
RN 160625-67-2 CAPLUS
CN Pregnan-20-one, 3-[(O-.beta.-D-glucopyranosyl-(1.fwdarw.6)-O-.beta.-D-glucopyranosyl-(1.fwdarw.4)-6-deoxy-3-O-methyl-.alpha.-L-mannopyranosyl)oxy]-21-(.beta.-D-glucopyranosyloxy)-14-hydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 6 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1991:24305 CAPLUS
DOCUMENT NUMBER: 114:24305
TITLE: Studies of steroids. Part CCL. Chemical conversion of corticosteroids to 3.alpha.,5.alpha.-tetrahydro derivatives. Synthesis of allotetrahydrocortisol glucuronides and allotetrahydrocortisone glucuronides
AUTHOR(S): [redacted] Hosoda, Hiroshi; Obana, Ken; Fukasawa, Ikuo; Nambara, Toshio
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SOURCE: [redacted] Chem. Pharm. Bull. (1990), 38(7), 1949-52
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:24305
AB The synthesis of the 3- and 21-glucuronides of allotetrahydrocortisol (allo-THF) and allotetrahyrocortisone (allo-THE) is described. 5.alpha.-Dihydrocortisol was prepd. by selective hydrogenation of 21-acetoxy-3,11.beta.,17.alpha.-trihydroxy-3,5-pregnadien-20-one 3-Et ether, followed by acid hydrolysis and sapon. When 5.alpha.-dihydrocortisol 21-tetrahydropyran ether was treated with potassium tri-sec-butylborohydride in THF under mild conditions, regioselective and stereoselective redn. at C-3 took place to give allo-THF 21-tetrahydropyranyl ether. This compd. was converted into the 3- and 21-monoacetates of allo-THF and allo-THE, key intermediates. Introduction of the glucuronyl residue at C-3 or C-21 was carried out by means of the Koenigs-Knorr reaction. Prior to sapon. yielding the 3-glucuronides, the alkali-sensitive ketol side chain at C-17 was protected as 20-semicarbazones.
IT 131061-52-4P 131061-53-5P 131061-60-4P
131061-61-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis of)
RN 131061-52-4 CAPLUS
CN Pregnane-11,20-dione, 3-(acetyloxy)-17-hydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 131061-53-5 CAPLUS
CN Pregnan-20-one,
3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,17-dihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.,11.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 131061-60-4 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.alpha.,11.beta.)-3-(acetyloxy)-11,17-dihydroxy-20-oxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
(prepn. and oxidn. or deprotection of)
RN 131061-51-3 CAPLUS
CN Pregnan-20-one,
3-(acetyloxy)-11,17-dihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 131061-50-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and O-acetylation of)
RN 131061-50-2 CAPLUS
CN Pregnan-20-one,
3,11,17-trihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 131061-62-6P 131061-63-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 131061-62-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.alpha.,11.beta.)-3,11,17-

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 131061-61-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.alpha.)-3-(acetyloxy)-17-hydroxy-11,20-dioxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI)
(CA INDEX NAME)



IT 131061-51-3P
RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 131061-63-7 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.alpha.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
hydroxy-20-oxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)



IT 103293-00-1P 103293-13-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 103293-00-1 CAPLUS
CN Pregnan-20-one, 3,17-dihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 103293-13-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.alpha.)-3,17-dihydroxy-20-

L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
oxopregnan-21-yl (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1986:200334 CAPLUS
DOCUMENT NUMBER: 104:200334
TITLE: Steroid glucuronide conjugates: analysis by thermospray liquid chromatography negative ion mass spectrometry
AUTHOR(S): Watson, D.; Taylor, G. W.; Murray, S.
CORPORATE SOURCE: Dep. Clin. Pharmacol., R. Postgrad. Med. Sch., London, W12 0HS, UK
SOURCE: Biomed. Environ. Mass Spectrom. (1986), 13(2), 65-9
CODEN: BEMSEN
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Thermospray neg. ion mass spectra of 18 steroid monoglucuronide conjugates were recorded. The salt-free aq. solvent system used gave mass spectra for glucuronides which contained mol. anions only. Selected ion monitoring indicated that as little as 100 pg of these compds. was detected. A gradient elution HPLC system was developed and applied to sepn. of the individual components of a mixt. of 12 steroid monoglucuronides and detection by thermospray liq. chromatog. neg. ion mass spectrometry.
IT 56162-41-5
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, by thermospray liq. chromatog.-mass spectrometry)
RN 56162-41-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



102

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1985:7010 CAPLUS
DOCUMENT NUMBER: 102:7010
TITLE: Synthesis of mono- and diglucosiduronates of metabolites of deoxycorticosterone and corticosterone and analysis by a new mass spectrometric technique
AUTHOR(S): Mattox, V. R.; Nelson, A. N.; Vrieze, W. D.; Jardine, I.
CORPORATE SOURCE: Dep. Biochem., Mayo Found., Rochester, MN, 55901, USA
SOURCE: Steroids (1983), 42(4), 349-64
CODEN: STEDAM; ISSN: 0039-128X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB By condensing 3.alpha.,21-dihydroxy-5.beta.-pregnan-20-one, or its monoacetate, with Me 2,3,4-tri-O-acetyl-1-bromo-1-deoxy-.alpha.-D-glucuronate in the Koenigs-Knorr reaction .beta.-D-glucosiduronates, e.g., I (R = Me, R1 = Ac, R2 = H), were obtained as polyacetate Me esters. Alk. hydrolysis cleaved the ester groups and gave the corresponding steroidal glucosiduronic acids, e.g., I (R = R1 = R2 = H). Upon treatment with diazomethane, these acids produced the equiv. Me esters. The C-3, the C-21 and the C-3,21 glucosiduronates of 3.alpha.,21-dihydroxy-5.beta.-pregnane-11,20-dione were prepd. by previously reported methods and converted into the corresponding C-20 semicarbazones. With C-20 stabilized by the semicarbazone group against redn., it was possible to reduce the 11-oxo function in these substances to an 11.beta.-hydroxyl group; after removal of the semicarbazone moiety from these products at pH 2.0, glucosiduronic acids were obtained, e.g., II gave I (R = R1 = H, R2 = OH). The mass spectra of a representative group of the mono- and diglucosiduronic acids and esters were detd. by utilizing fast atom bombardment and monitoring ions in both pos. and neg. modes of operation.
IT 56162-37-9P 56162-41-5P 56316-34-8P 93524-34-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and esterification of, with diazomethane)
RN 56162-37-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56162-41-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 56316-34-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
(prepn. and hydrolysis of)

RN 93524-33-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11-hydroxy-20-oxopregnane-3,21-diyl bis-, dimethyl ester, 2,2',3,3',4,4'-hexaacetate (9CI) (CA INDEX NAME)



RN 93564-46-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-(acetyloxy)-20-oxopregnan-21-yl, methyl ester, triacetate (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 93524-34-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.beta.,5.alpha.,11.beta.)-11-hydroxy-20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



IT 93524-33-5P 93564-46-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



IT 93524-27-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sapon. of)

RN 93524-27-7 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-20-oxopregnane-3,21-diyl bis-, dimethyl ester, hexaacetate (9CI) (CA INDEX NAME)



IT 36707-58-1P 73847-70-8P 73847-72-0P 73847-77-5P 73856-90-3P 93524-28-8P

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
93549-78-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 36707-58-1 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.beta.)-11,20-dioxopregnane-
3,21-diyl bis-, dimethyl ester, hexaacetate (9CI) (CA INDEX NAME)



RN 73847-70-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-
oxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 73847-72-0 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-
dihydroxy-20-oxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)



RN 73847-77-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.beta.,11.beta.)-11-hydroxy-
20-oxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 73856-90-3 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.beta.)-20-oxopregnane-3,21-
diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 93524-28-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.beta.)-20-oxopregnane-3,21-

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
diyl bis-, diammonium salt (9CI) (CA INDEX NAME)



RN 93549-78-1 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3-
(acetyloxy)-11-hydroxy-20-oxopregnan-21-yl, methyl ester,
2,3,4-triacetate
(9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1984:451073 CAPLUS
DOCUMENT NUMBER: 101:51073
TITLE: Analysis of steroid and vitamin D glucuronides and sulfates by fast atom bombardment mass spectrometry
AUTHOR(S): Jardine, Ian; Scanlan, Gale F.; Mattox, Vernon R.; Kumar, Rajiv
CORPORATE SOURCE: Dep. Pharmacol. Cell Biol. Endocrinol., Mayo Found., Rochester, MN, 55905, USA
SOURCE: Biomed. Mass Spectrom. (1984), 11(1), 4-9
CODEN: BMSYAL; ISSN: 0306-042X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The direct anal. of underivatized steroid and vitamin D glucuronide and sulfate conjugates by pos.- and neg.-ion fast-atom-bombardment mass spectrometry was demonstrated. A sample of each compd. was prepd. in a glycerol soln. and deposited on a Cu-tipped direct insertion probe. The sample and mass spectrometer source were held at ambient temp. Mass spectrometer was operated at 6 kV accelerating potential and the mass scale was calibrated by the data system with PEG of av. mol. wt. 600. A primary atom beam of Xe was produced by a saddle field ion source. This method allows unambiguous mol. wt. detn. and provides useful fragmentation information. Anal. of low microgram quantities of such conjugates purified from biol. sources was done, e.g., the monoglucuronide of 1,25-dihydroxyvitamin D3 and the .beta.-D-glucosiduronic acid of fluorescein. Thus, this method is an extremely useful complementary technique to electron-impact mass spectrometry.
IT **36707-59-2 36707-60-5 56162-42-6**
RL: PRP (Properties)
(mass spectrum of, pos.-ion fast-atom-bombardment)
RN 36707-59-2 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-60-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 56162-42-6 CAPLUS

L4 ANSWER 12 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)



102

L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1984:115104 CAPLUS
DOCUMENT NUMBER: 100:115104
TITLE: Studies on steroids. CLXXXIX. Preparation of haptens for use in immunoassays of tetrahydro-11-deoxycortisol and its glucuronides
AUTHOR(S): Hosoda, Hiroshi; Yokohama, Hiromitsu; Ishii, Kazuo; Ito, Yuko; Nambara, Toshio
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SOURCE: Chem. Pharm. Bull. (1983), 31(11), 4001-7
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Tetrahydro-11-deoxycortisol haptens including the 3-hemisuccinate [79489-05-7], 21-hemisuccinate [89155-00-0], 3-hemiglutarate [79489-08-0], 21-hemiglutarate [89155-01-1], 3-glucuronide [56162-40-4], 21-glucuronide [56162-38-0], and 3,21-diglucuronide (I) [89155-02-2] were synthesized for the purpose of developing immunoassays for tetrahydro-11-deoxycortisol or its glucuronides. Antisera were elicited in 2 rabbits by immunization with the bovine serum albumin conjugate of I. The antisera had binding affinities to enzyme-labeled antigens prepd. from the 3-hemisuccinate, 3-hemiglutarate, and I.
IT **89154-99-4P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and conjugation of, with bovine serum albumin)
RN 89154-99-4 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-21-[(2,5-dioxo-1-pyrrolidinyl)oxy]-17-hydroxy-20-oxopregnan-3-yl (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



IT 89154-97-2P 89154-98-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sapon. of)
RN 89154-97-2 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-(acetyloxy)-17-hydroxy-20-oxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 89154-98-3 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-17-hydroxy-20-oxopregnane-3,21-diyl di-, dimethyl ester, 2,2',3,3',4,4'-hexaacetate (9CI) (CA INDEX NAME)



IT 56162-38-0P 89155-02-2P

L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as hapten)
RN 56162-38-0 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 89155-02-2 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-17-hydroxy-20-oxopregnane-3,21-diyl di- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

L4 ANSWER 14 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1982:563317 CAPLUS
DOCUMENT NUMBER: 97:163317
TITLE: Studies on steroids. Part CLXXVI. Synthesis of haptens for use in immunoassays of tetrahydrocortisol, tetrahydrocortisone and their glucuronides
AUTHOR(S): Hosoda, Hiroshi; Saito, Keiko; Ito, Yuko; Yokohama, Hiromitsu; Ishii, Kazuo; Nambara, Toshio
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SOURCE: Chem. Pharm. Bull. (1982), 30(6), 2110-18
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In order to develop specific and sensitive immunoassays, carboxylated derivs. of tetrahydrocortisol and tetrahydrocortisone were synthesized.
The prepn. of the 3-hemisuccinates, 21-hemisuccinates, 3-hemiglutarates, and 21-hemiglutarates of these corticosteroids was carried out starting from cortisol 21-acetate. Tetrahydrocortisol monoglucuronides and tetrahydrocortisone monoglucuronides were also prepd.
IT **56162-42-6P 56162-45-9P 83274-86-6P**
83274-87-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 56162-42-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 83274-87-7 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-(acetyloxy)-17-hydroxy-11,20-dioxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

RN 56162-45-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 83274-86-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3-(acetyloxy)-11,17-dihydroxy-20-oxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1981:12421 CAPLUS
DOCUMENT NUMBER: 94:12421
TITLE: Some experiences on radioimmunoassays of synthetic glucocorticoids
AUTHOR(S): Haack, D.; Vecsei, P.; Lichtwald, K.; Klee, H. R.; Gless, K. H.; Weber, M.
CORPORATE SOURCE: Pharmakol. Inst., Univ. Heidelberg, Heidelberg, D-6900, Fed. Rep. Ger.
SOURCE: Allergologie (1980), 3(5), 259-67
CODEN: ALLRDI; ISSN: 0344-5062
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Antibodies to betamethasone, dexamethasone, beclomethasone, prednisolone, 6-methylprednisolone, and triamcinolone were raised, characterized, and used in radioimmunoassays (RIAs). While antibodies to betamethasone, dexamethasone, and, to a lesser extent, triamcinolone were specific, specific antibodies to prednisolone and 6-methylprednisolone have not been raised. One of the main problems of synthetic glucocorticoid RIA is the interference by endogenous steroids, e.g., cortisol. The interference of endogenous steroids in RIAs of triamcinolone, prednisolone, and 6-methylprednisolone could be decreased by forming derivs. of the endogenous steroids by using the Girard reagent. Improvement of the RIAs, esp. in the case of dexamethasone and betamethasone, could also be achieved by the presence of corticosteroid-binding globulins in simple direct assays performed in unprocessed plasma samples. Practical experiences with betamethasone and dexamethasone RIAs are presented.
IT **56162-45-9**
RL: ANST (Analytical study)
(glucocorticoid radioimmunoassay cross reaction with)
RN 56162-45-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 16 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1980:618513 CAPLUS
DOCUMENT NUMBER: 93:218513
TITLE: Corticosteroids in human blood. VII. Isolation, characterization, and quantitation of glucuronide-conjugated metabolites of cortisol in human plasma
AUTHOR(S): Kornel, Ludwig; Saito, Zenzo; Yuan, Larry C.
CORPORATE SOURCE: Steroid Unit, Rush-Presbyt.-St. Luke's Med. Cent., Chicago, IL, 60612, USA
SOURCE: J. Steroid Biochem. (1980), 13(7), 751-71
CODEN: JSTBBK; ISSN: 0022-4731
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Six steroid sulfoglucuronides, 7 steroid diglucuronides, and 22 steroid monoglucuronide conjugated metabolites of cortisol were isolated from human plasma 2.25-2.5 h after i.v. administration of cortisol-4-14C, and their structure and quant. relation detd. Of all plasma metabolites of cortisol, total free and conjugated metabolites constituted 47.5 and 52.5%, resp. Of the latter, monoglucuronides, diglucuronides, and sulfoglucuronides constituted 86.0, 1.8, and 1.3%, resp. The relative plasma concns. of individual conjugates were similar to those of the urinary steroids. The quant. relations between concns. of various individual conjugates suggest certain substrate predilections of steroid glucuronyltransferases and sulfotransferases.

IT **56162-45-9 75544-00-2 75544-01-3**
75544-02-4
RL: BIOL (Biological study)
(as cortisol metabolite, of blood plasma)

RN 56162-45-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 75544-00-2 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11,17-dihydroxy-20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 75544-01-3 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.alpha.,11.beta.)-11,17-dihydroxy-20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 75544-02-4 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-17-hydroxy-11,20-dioxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1980:460554 CAPLUS
DOCUMENT NUMBER: 93:60554
TITLE: Liquid ion exchangers in paper chromatography of steroidal glucosiduronic esters
AUTHOR(S): Mattox, Vernon R.; Litwiller, Robert D.
CORPORATE SOURCE: Mayo Found. Mayo Grad. Sch., Rochester, MN, 55901, USA
SOURCE: J. Chromatogr. (1980), 189(1), 33-42
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Twenty-five steroidal glucosiduronic esters were chromatographed on paper in each of 5 straight-phase systems and 5 reversed-phase systems. The resolving characteristics of these systems were compared by expressing the retention values in terms of RM and correlating the data by use of linear regression equations. The resolving characteristics of the straight-phase systems as a group are very similar, and those of the reversed-phase systems are somewhat less similar; the various systems differ considerably in polarity. The resolving properties of a straight-phase system and a reversed-phase system which contain the same liq. ion exchanger are markedly different, a circumstance which increases the probability that a pair of compds. which was not sepd. in a straight-phase system will be resolved in the reversed-phase system which contains the same liq. ion exchanger. The migration of the esters in the foregoing systems was compared with the migration of the corresponding glucosiduronic acids (a previous study) in the same solvent systems. If a particular pair of conjugates is not separable as carboxylic acids in a specific straight-phase system, there is a relatively good chance that they will be separable as Me esters in the same system.

IT 36707-59-2 73847-70-8 73847-72-0
73847-73-1 73847-76-4 73847-77-5
73856-88-9 73856-90-3
RL: ANST (Analytical study)
(paper chromatog. of, liq. ion exchangers in reversed-phase and straight-phase)

RN 36707-59-2 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 73847-70-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)



RN 73847-72-0 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-dihydroxy-20-oxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 73847-73-1 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)



RN 73847-76-4 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 73847-77-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11-hydroxy-20-oxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 73856-88-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 73856-90-3 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-20-oxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)



IT 36707-54-7P
RL: ANST (Analytical study); PREP (Preparation)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
(prepn. of)

RN 36707-54-7 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-dioxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1977:596703 CAPLUS
DOCUMENT NUMBER: 87:196703
TITLE: Radioimmunoassays of tetrahydrocortisone and tetrahydrocortisol in human urine
AUTHOR(S): Will, H.; Aderjan, R.; Winkler, T.; Penke, B.; Vecsei, P.
CORPORATE SOURCE: Dep. Pharmacol., Univ. Heidelberg, Heidelberg, Ger.
SOURCE: Acta Endocrinol. (Copenhagen) (1977), 86(2), 369-79
CODEN: ACENA7
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A simple radioimmunoassay for the detn. of tetrahydrocortisone (THE), tetrahydrocortisol (THF), and their 21-glucosiduronate conjugates is described. White New Zealand rabbits were immunized with THF- and THE-20-oxime-bovine serum albumin conjugates. The resulting antiserums were very specific. Both allo-THE and allo-THF gave min. crossreactions; however, THE- and THF-21-glucosiduronate bind with the corresponding antibodies at a level of 100%. The following types of estns. were introduced: estn. of the sum of unconjugated THF and THF-21-glucosiduronate in highly dild. unprocessed human urine; a similar estn. of THE and THF-21-glucosiduronate; and estn. of THF or THE after .beta.-glucuronidase treatment and diln. without further procedures. THF and THE values correlated significantly with known parameters that characterize cortisol prodn., such as cortisol secretion rate and the urinary corticoid (C21-.alpha.-ketosteroid) levels.

IT 56162-42-6 56162-45-9
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, in urine by radioimmunoassay)

RN 56162-42-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56162-45-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56162-38-0 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 56162-41-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 56316-33-7 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11-hydroxy-20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 56316-34-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56162-42-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 56162-45-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-

L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 21 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1975:590726 CAPLUS
DOCUMENT NUMBER: 83:190726
TITLE: Steroid conjugates. VIII. Isolation and characterization of glucuronide-conjugated metabolites of cortisol in human urine
AUTHOR(S): Kornel, Ludwig; Saito, Zenzo
CORPORATE SOURCE: Steroid Unit, Rush-Presbyt.-St. Luke's Med. Cent., Chicago, Ill., USA
SOURCE: J. Steroid Biochem. (1975), 6(8), 1267-84
CODEN: JSTBBK
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A total spectrum of glucuronide-conjugated metabolites of cortisol (22 steroid monoglucuronides and 7 steroid diglucuronides) was isolated from human urine and characterized. Following i.v. administration of a tracer dose of 14C-labeled cortisol to 10 normal subjects, urine was collected for 2 consecutive 24-hr periods. Free steroids were removed and all conjugated metabolites were extd. by Amberlite XAD-2 chromatog. and were further purified by chromatog. on a polyethyleneimine-impregnated cellulose column. Groups of mono- and diglucuronide conjugated steroids were sepd. from each other and from other groups of steroid conjugates by high-voltage paper electrophoresis. Individual monoglucuronide-conjugated metabolites were sepd. from each other by consecutive paper chromatographies and their homogeneity ascertained. Each steroid conjugate was then characterized. The following monoglucuronide-conjugated (-G) metabolites of cortisol were isolated: cortisol-21-G, cortisone-21-G, 20.beta.-dihydrocortisol-21-G, tetrahydrocortisol-3-G, tetrahydrocortisol-21-G, 5.alpha.-tetrahydrocortisol-3-G, tetrahydrocortisone-3-G, 5.alpha.-tetrahydrocortisone-3-G, cortol-20.alpha.-3-G, 5.alpha.-cortol-20.alpha.-3-G, cortol-20.beta.-3-G, 5.alpha.-cortol-20.beta.-3-G, cortolone-20.alpha.-3-G, 5.alpha.-cortolone-20.alpha.-3-G, cortolone-20.beta.-3-G, 5.alpha.-cortolone-20.beta.-3-G, 11-hydroxyaetiocholanolone-3-G, 11-hydroxyandrosterone-3-G, 11-oxoaetiocholanolone-3-G, 11-oxoandrosterone-3-G. In addn., 6.beta.-hydroxy-20.beta.-dihydrocortisol and 6.beta.-hydroxy-20.beta.-cortol were isolated as monoglucuronides, but their site of conjugation was not detd. The steroids identified as diglucuronide conjugates were: cortol-20.alpha. and -20.beta., cortolone-20.alpha. and -20.beta., tetrahydrocortisol, 5.alpha.-tetrahydrocortisol and tetrahydrocortisone. Three of the isolated metabolites were not known to exist as glucuronide conjugates.

L4 ANSWER 21 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
The quantitation of individual steroid conjugates revealed interesting relations between various metabolites.

IT **56162-45-9**
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(of urine)

RN 56162-45-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1975:455414 CAPLUS
DOCUMENT NUMBER: 83:55414
TITLE: Liquid ion exchangers in paper chromatography of steroidal glucosiduronic acids, glucosiduronic esters, and free steroids. Influence of concentration of exchanger and counterion
AUTHOR(S): Mattox, V. R.; Goodrich, June E.; Litwiller, Robert D.
CORPORATE SOURCE: Mayo Clin. and Mayo Found., Rochester, Minn., USA
SOURCE: J. Chromatogr. (1975), 108(1), 23-35
CODEN: JOCRAM
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The chromatog. mobility of steroidal glucosiduronic acids on paper in CHCl3-formamide increases as the concn. of ion exchanger in the CHCl3 phase increases; mobility decreases as the concn. of counterion in formamide increases. Mobility of glucosiduronic esters and of hydroxylated free steroids increases with an increase in concn. of exchanger; small changes in concn. of counterion in the stationary phase do not alter the migration of these nonionizable compds. Data are presented that suggest that partition of the glucosiduronic acids between the 2 phases occurs predominantly by an ion-exchange process and that H bonding plays a secondary role. Partition of the glucosiduronic esters and hydroxylated free steroids appears to occur primarily by a H bonding process.

IT **36707-59-2 36707-60-5**
RL: ANT (Analyte); ANST (Analytical study)
(chromatog. of, paper, liq. ion exchangers in)

RN 36707-59-2 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-60-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1975:439624 CAPLUS
DOCUMENT NUMBER: 83:39624
TITLE: Liquid ion exchangers in paper chromatography of steroidal glucosiduronic acids. Influence of different exchangers on the mobility in chloroform-formamide and correlation of chromatographic data
AUTHOR(S): Mattox, Vernon R.; Litwiller, Robert D.; Goodrich, June E.
CORPORATE SOURCE: Mayo Clin. and Mayo Found., Rochester, Minn., USA
SOURCE: J. Chromatogr. (1975), 109(1), 129-47
CODEN: JOCRAM
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A group of 25 steroidal glucosiduronic acids was chromatog. on paper in CHCl3-formamide in the presence of several different liq. ion exchangers. Chromatograms were run also in 3 Bush-type systems. The Rf values were converted into Rm values, and the data were correlated by use of a series of regression equations of the type Rm(Y) = a(Rm(X) + b, in which X designated a std. system to which each other system (Y) was compared. The ratio of the slope a to the correlation coeff. r was a measure of the resolving power of system Y relative to the std. system; intercept b, in assocn. with slope a, was an indication of the polarity of system Y relative to X. The correlation coeff. r, and the std. error of est. were indications of whether solvent systems Y and X had very similar or relatively different resolving properties for a group of solutes. The regression equations were useful for correlating chromatog. data obtained from a group of compds. in several solvent systems. Properties of the chromatog. systems were discussed, and the relative importance of ion exchange and H-bonding with the various solvent systems was pointed out. The .DELTA.RMr and .DELTA.RMr values were given for functional groups at several locations in the conjugates for 10 of the chromatog. systems.

IT **36707-55-8 36707-60-5 56162-37-9 56162-38-0 56162-41-5 56162-42-6 56162-45-9 56316-33-7 56316-34-8**
RL: ANT (Analyte); ANST (Analytical study)
(chromatog. of, paper, liq. ion-exchangers for)

RN 36707-55-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-60-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)

10-2



RN 56162-37-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56162-38-0 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 56162-41-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56162-42-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 56162-45-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56316-33-7 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.beta.,11.beta.)-11-hydroxy-
20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 56316-34-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid,
(3.alpha.,5.beta.)-20-oxopregnane-3,21-

L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
diyl bis- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1974:37397 CAPLUS
DOCUMENT NUMBER: 80:37397
TITLE: Pregnane derivatives
INVENTOR(S): Phillips, Gordon Hanley; Lawrence, Robin; Newall, Christopher E.; Wright, Michael
PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.
SOURCE: Ger. Offen., 58 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2322560	A1	19731115	DE 1973-2322560	19730504
GB 1432135	A	19760414	GB 1972-21145	19730504
			GB 1972-21145	19720505

PRIORITY APPLN. INFO.:
AB Pregnanediones I-VIII (R = alkyl, aryl, morpholinoalkyl, piperidinoalkyl)
(45 compds.), possessing anesthetic activity, were prepd. from 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione (II). Thus, II
was treated with EtSH to give VII (R = Et). I-VI and VIII were prepd. similarly.
IT 51087-29-7P 51087-32-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 51087-29-7 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-32-2 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-,
(3.alpha.,5.beta.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 24 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 36707-61-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis-, diammoniate (9CI) (CA INDEX NAME)



RN 36707-63-8 CAPLUS

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
CN .alpha.-D-Glucopyranuronic acid, 1,2-O-[1-[[(3.alpha.,5.beta.)-11,20-dioxo-21-[(2,3,4-tri-O-acetyl-6-methyl-.beta.-D-glucopyranuronosyl)oxy]pregnan-3-yl]oxy]ethylidene]-, methyl ester, diacetate, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 36763-75-4 CAPLUS
CN .alpha.-D-Glucopyranuronic acid, 1,2-O-[1-[[(3.alpha.,5.beta.)-3-(acetyloxy)-11,20-dioxopregnan-21-yl]oxy]ethylidene]-, methyl ester, diacetate (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1971:498741 CAPLUS
DOCUMENT NUMBER: 75:98741
TITLE: 3.beta.,5.beta.,14.beta.,21-Tetrahydroxypregnan-20-one
INVENTOR(S): Stache, Ulrich; Haede, Werner; Fritsch, Werner; Radscheit, Kurt
PATENT ASSIGNEE(S): Farbwerke Hoechst A.-G.
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2003653	A	19710805	DE 1970-2003653	19700128
GB 1345041	A	19740130	GB 1971-2248	19710118
GB 1345042	A	19740130	GB 1973-30724	19710118
NL 7100872	A	19710730	NL 1971-872	19710122
CH 559756	A	19750314	CH 1971-1070	19710125
BE 762055	A1	19710726	BE 1971-98981	19710126
US 3732210	A	19730508	US 1971-109932	19710126
FR 2077028	A5	19711015	FR 1971-2630	19710127
DK 125792	B	19730507	DK 1971-357	19710127
CA 942295	A1	19740219	CA 1971-103755	19710127
AT 320871	B	19750310	AT 1971-660	19710127

PRIORITY APPLN. INFO.: DE 1970-2003653 19700128

AB The title compd. (I), an important intermediate in the prepn. of periplogenin, was prepd. from 21-hydroxypregna-4,14-diene-3,20-dione (II).
Thus, II was treated with ethylene glycol in the presence of p-MeC6H4SO3H to give 3,3.20,20-bis(ethylenedioxy)-21-hydroxypregna-5,14-diene (III).
III acetate was partially deketalized to yield 20,20-(ethylenedioxy)-21-acetoxypregna-4,14-dien-3-one, reduced with LiAlH4 in THF and acylated with Ac2O in pyridine to give 20,20-(ethylenedioxy)-3.beta.-21-diacetoxypregna-4,14-diene. Reaction of this with PhSO2NBr2 in aq. HOAc-dioxane gave 5.alpha.,15.alpha.-dibromo-20,20-(ethylenedioxy)-3.beta.,21-diacetoxy-4.beta.,14.beta.-dihydroxypregnane, treatment of which with aq. KOH in MeOH and redn. of the product with LiAlH4 in THF yielded 20,20-(ethylenedioxy)-3.beta.,5.beta.,14.beta.,21-tetrahydroxypregnane, which was deketalized to give I.

IT 33439-97-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 33439-97-3 CAPLUS
CN 5.beta.,14.beta.-Pregnan-20-one, 5,14-dihydroxy-3.beta.,21-bis[(tetrahydro-2H-pyran-2-yl)oxy]- (8CI) (CA INDEX NAME)

Absolute stereochemistry.

=> d ibib ab hitstr 1-3

L5 ANSWER 1 OF 3 USPATFULL
ACCESSION NUMBER: 1999:96496 USPATFULL
TITLE: Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States
Xia, Haiji, Foothill Ranch, CA, United States
Hogenkamp, Derk, Carlsbad, CA, United States
PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5939545	19990817
APPLICATION INFO.:	US 1997-887229	19970702 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-389820, filed on 14 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-346927, filed on 23 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-196919, filed on 14 Feb 1994, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Dees, Jose G.
ASSISTANT EXAMINER: Badio, Barbara
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
IT 162883-05-8P
(prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)
RN 162883-05-8 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 USPATFULL (Continued)



L5 ANSWER 2 OF 3 USPATFULL
ACCESSION NUMBER: 1999:81822 USPATFULL
TITLE: Neuroactive steroids of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States
Fick, David B., Mission Viejo, CA, United States
Hogenkamp, Derk J., Carlsbad, CA, United States
Lan, Nancy C., South Pasadena, CA, United States
PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5925630	19990720
APPLICATION INFO.:	US 1996-659192	19960606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-467404, filed on 6 Jun 1995
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Badio, Barbara
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 3047
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural Formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 =methyl), 19-norandrostanes, and norpregnanes (R.sub.4 =H).
IT 186264-74-4P
(prepn. of neuroactive steroids of androstane and pregnane series)
RN 186264-74-4 USPATFULL
CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



IT 162883-05-8P 186264-24-4P 186264-27-7P
186264-34-6P 186264-35-7P 186264-36-8P
186264-37-9P 186264-38-0P 186264-54-0P
186264-61-9P 186264-63-1P 186264-79-9P
186264-84-6P 186264-85-7P 186264-86-8P
186264-87-9P 203719-57-7P 230958-75-5P
(prepn. of neuroactive steroids of androstane and pregnane series)
RN 162883-05-8 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 186264-24-4 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-27-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



● I⁻

RN 186264-37-9 USPATFULL
CN Pyridinium, 4-[[(3.alpha.,5.alpha.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 186264-38-0 USPATFULL
CN Pyridinium, 4-[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-35-7 USPATFULL
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-36-8 USPATFULL
CN Pyridinium, 4-[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



● I⁻

RN 186264-54-0 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-61-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-63-1 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-79-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-84-6 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-85-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-86-8 USPATFULL
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 186264-87-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 203719-57-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 230958-75-5 USPATFULL
CN Pyridinium, 4-[[(2.beta.,3.beta.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



● I⁻

L5 ANSWER 3 OF 3 USPATFULL

ACCESSION NUMBER: 76:29138 USPATFULL
TITLE: Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position
INVENTOR(S): Phillipps, Gordon Hanley, Wembley, England
Lawrence, Robin, Stoke Poges, England
Newall, Christopher Earle, London, England
Wright, Michael, Stoke Poges, England
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3959260	19760525
APPLICATION INFO.:	US 1974-488989	19740716 (5)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1973-356097, filed on 1 May 1973, now Defensive Publication No.	
PRIORITY INFORMATION:	GB 1972-21145	19720505

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 1493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the compounds possessing a 3.alpha.-hydroxy group, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position the residue of a sulphur nucleophile or a sulphone or sulphoxide grouping.

IT **51087-29-7P 51087-32-2P**
(prepn. of)
RN 51087-29-7 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 3 USPATFULL (Continued)



RN 51087-32-2 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> d his

     (FILE 'HOME' ENTERED AT 15:16:20 ON 17 NOV 1999)

     FILE 'REGISTRY' ENTERED AT 15:16:31 ON 17 NOV 1999
L1              STRUCTURE UPLOADED
L2            0 S L1
L3           94 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 15:19:32 ON 17 NOV 1999
L4           29 S L3

     FILE 'USPATFULL' ENTERED AT 15:23:40 ON 17 NOV 1999
L5            3 S L3
```

L4 ANSWER 26 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 27 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
CN Pregnan-20-one, 6-(dihydroxymethyl)-9-fluoro-3.alpha.,11.beta.,17-trihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-16-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-, 6,6-diacetate (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 27 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1970:425761 CAPLUS
DOCUMENT NUMBER: 73:25761
TITLE: Antiinflammatory 9.alpha.-Fluoro-11.beta.,17.alpha.,21-trihydroxy-16-hydroxymethyl-6-(dihydroxy)methyl-1,4-pregnadiene-3,20-diones
INVENTOR(S): Krsek, George
PATENT ASSIGNEE(S): Rachelle Laboratories, Inc.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3494943	A	19700210	US 1967-694426	19671229

AB The title compd. is prepd. from 9.alpha.-fluoro-3.alpha.,11.beta.,17.alpha.,21-tetrahydroxy-16-(hydroxymethyl)pregnan-20-one in 10 conventional steps, including a catalytic formylation and fermentation with Corynebacterium [Arthrobacter] simplex.
IT 27406-07-1P 27406-09-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 27406-07-1 CAPLUS
CN Pregnan-20-one, 9-fluoro-3.alpha.,11.beta.,17-trihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-16-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 27406-09-3 CAPLUS

L4 ANSWER 28 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1970:90745 CAPLUS
DOCUMENT NUMBER: 72:90745
TITLE: Antiinflammatory bicyclo[2.2.2]octane-1-carboxylate, bicyclo[2.2.2]oct-1-yl-methyl carbonate, and adamantylmethyl carbonate esters of the 4-pregnene series
INVENTOR(S): Cross, Alexander D.; Fried, John H.
PATENT ASSIGNEE(S): Syntex Corp.
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3484436	A	19691216	US 1967-665996	19670907

AB The title compds. show corticoid and antiinflammatory activity. Thus, a mixt. of 2.5 g pregn-4-ene-11.beta.,17.alpha.,21-triol-3,20-dione (I) in 15 ml pyridine contg. 4.0 g bicyclo[2.2.2]octane-1-carbonyl chloride was heated at steam bath temp. 2 hr to yield 21-(bicyclo[2.2.2]-oct-1-ylcarbonyloxy)pregn-4-ene-11.beta.,17.alpha.-diol-3,20-dione. Similarly prepd. were the other analogous title esters. Dihydropyran (2 ml) was added to a soln. of 1 g I in 150 ml C6H6, about 1 ml distd., 0.4 g p-MeC6H4SO3H added, and the mixt. keptat room temp. 4 hr to yield 21-(tetrahydropyran-2-yloxy)pregn-4-ene-11.beta.,17.alpha.-diol-3,20-dione (II); 200 ml II in 32 ml iso-PrOH and25 mg NaBH4 was stirred at room temp. 15 hr to yield 21-(tetrahydropyran-2-yloxy)pregn-4-ene-3.beta.,11.beta.,17.alpha.-triol-20-one (III); III 3.beta.-(bicyclo[2.2.2]octane-1-carboxylate) (1 g) in 30 ml HOAc wastreated with 0.5 ml 2N HCl to yield 3.beta.-(bicyclo[2.2.2]octane-1-carbonyloxy)pregn-4-ene-11.beta.,17.alpha.,21-triol-20-one. A mixt. of 2 g I, 4 mg p-MeC6H4SO3H, and 800 ml C6H6 was treated with 1.5 ml bicyclo[2.2.2]-oct-1-yltrimethoxymethane and a few drops pyridine to give 17.alpha.,21-[(methoxybicyclo[2.2.2]oct-1-yl)methylidenedioxy]pregn-4-en-11.beta.-ol-3,20-dione, which (1 g) in 30 ml EtOHwas treated with 0.5 ml 2N HCl to yield 17.alpha.-(bicyclo-[2.2.2]octane-1-carbonyloxy)pregn-4-ene-11.beta.,21-diol-3,20-dione. Other similar compds. are mentioned.
IT 26144-15-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 26144-15-0 CAPLUS
CN Pregn-4-en-20-one, 3.beta.,11.beta.,17-trihydroxy-21-[(tetrahydro-2H-pyran-

L4 ANSWER 28 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
2-yl)oxy]- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 29 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1969:58144 CAPLUS
DOCUMENT NUMBER: 70:58144
TITLE: 9.alpha.-Difluoromethyl- and 9.alpha.-trifluoromethylpregnenes
INVENTOR(S): Fried, John H.
PATENT ASSIGNEE(S): Syntex Corp.
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3409610	A	19681105	US 1966-560864	19660627

AB 3.alpha.,17.alpha.,21-Trihydroxy-5.beta.-pregnane-11,20-dione 21-acetate (1 g.), 1 g. KHCO3, 10 ml. H2O, and 90 ml. MeOH was kept under N 5 hrs. at room temp. to give 3.alpha.,17.alpha.,21-trihydroxy-5.beta.-pregnane-11,20-dione (I). I (5 g.) in 200 ml. CHCl3 was mixed with 40 ml. 37% aq. HCHO and 5 ml. concd. HCl, and the mixt. stirred 48 hrs. at room temp. to give

17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-hydroxy-5.beta.-pregnan-11-one (II). II (1 g.), 4 ml. C5H5N, and 2 ml. Ac2O was kept 15 hrs. at room temp. to give 17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-acetoxy-5.beta.-pregnan-11-one (III). Br in dioxane (1.2 molar equivs.) was added dropwise to 1 g. III in dioxane at 15.degree., a few drops anhyd. HBr in CHCl3 added, and the mixt. kept 30 min. at room temp. to give

17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-acetoxy-9.alpha.-bromo-5.beta.-pregnan-11-one (IV). Li (3 molar equivs.) was added slowly to 2 g. IV in 30 ml. anhyd. tetrahydrofuran (THF) and 50 ml. anhyd. liq. NH3 at -35 to -40.degree., stirring continued 30 min., then 3 molar equivs. AcCl in tetrahydrofuran added, and the mixt. kept 30 min. to give

17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.,11-diacetoxy-5.beta.-pregn-9(11)-ene (V). Na chlorodifluoroacetate (30 equivs.) in 30 ml. diglyme was added dropwise over 2 hrs. at reflux to 1 g. V in 8 ml. diglyme, and refluxing continued until the reaction was complete to give

L4 ANSWER 29 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.,11.beta.-diacetoxy-9.alpha.,11.alpha.-difluoromethylene-5.beta.-pregnane (VI). VI (1 g.) in 50 ml. MeOH was refluxed 3 hrs. with 0.2 g. KOH in 1 ml. H2O to give 17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-hydroxy-9.alpha.-difluoromethyl-5.beta.-pregnan-11-one (VII). VII (6 g.) in 120 ml. C5H5N was added to 6 g. CrO3 in 20 ml. C5H5N, and the mixt. kept at room temp. 15 hrs. to give 17.alpha.,20:20,21-bis(methylenedioxy)-9.alpha.-difluoromethyl-5.beta.-pregnane-3,11-dione (VIII). A few drops 15% HBr in HOAc was added to 1 g. VIII in 17 ml. CHCl3 and 20 ml. HOAc at -10.degree., then 0.46 g. Br in 12 ml. CHCl3 added, followed by 2.5 g. NaOAc in 17 ml. H2O to give the 4-bromo deriv. (IX). IX (1 g.) in 20 ml. HCONMe2 contg. 0.5 g. LiCl was stirred under N 4 hrs. on a stream bath, cooled to 10.degree., and 11 ml. H2O added to give 17.alpha.,20:20,21-bis(methylenedioxy)-9.alpha.-difluoromethylpregn-4-ene-3,11-dione (X). X (1 g.) in 100 ml. 80% HOAc was heated at 90.degree. under N 7 hrs. to give

9.alpha.-difluoromethyl-17.alpha.,21-dihydroxypregn-4-ene-3,11,20-trione. V (5 g.), 2.5 ml. anhyd. C5H5N, and 10 ml. F3CI was irradiated (high-pressure lamp) 72 hrs. at 4 cm. to give 17.alpha.,20:-20,21-bis(methylenedioxy)-3.alpha.-acetoxy-9.alpha.-trifluoromethyl-5.beta.-pregnan-11-one.
9.alpha.-Trifluoromethyl-17.alpha.,21-dihydroxypregn-4-ene-3,11,20-trione (0.5 g.), 10 ml. dioxane, and 0.35 g. 2,3-dichloro-5,6-dicyano-1,4-benzoquinone was refluxed 10 hrs. to give 9.alpha.-trifluoromethyl-17.alpha.,21-dihydroxypregna-1,4-diene-3,11,20-trione. Prepd. similarly were a long series of analogs. No phys. properties were given.

IT 21365-47-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21365-47-9 CAPLUS
CN Pregn-4-ene-11,20-dione, 17-hydroxy-3.beta.,21-bis[(tetrahydro-2H-pyran-2-yl)oxy]-9-(trifluoromethyl)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 29 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L7 ANSWER 62 OF 65 USPATFULL
ACCESSION NUMBER: 75:16911 USPATFULL
TITLE: Reduction of 3-keto-5 beta-H steroids to 3 beta-hydroxy-5beta-H steroids
INVENTOR(S): Nickolson, Robert C., Ulrich Kerb, Germany, Federal Republic of
Wiechert, Rudolf, Berlin, Germany, Federal Republic of
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin and Bergkamen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3875195	19750401
APPLICATION INFO.:	US 1973-416095	19731115 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1972-2257132	19721118

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: French, Henry A.
LEGAL REPRESENTATIVE: Millen, Raptes & White
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 214
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 3-KETO-5.beta.-H steroids are reduced to 3.beta.-hydroxy-5.beta.-H steroids with hydrogen under pressure and Raney nickel catalyst in a lower carboxylic acid as solvent.
IT **601-03-6P 800-10-2P 10147-45-2P 15734-50-6P 53604-15-2P 53604-17-4P**
(prepn. of)
RN 601-03-6 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 62 OF 65 USPATFULL (Continued)



RN 53604-15-2 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3,17-dihydroxy-, (3.beta.,5.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 53604-17-4 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.beta.,5.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 62 OF 65 USPATFULL (Continued)
RN 800-10-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10147-45-2 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.beta.,5.beta.)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 15734-50-6 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.beta.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 62 OF 65 USPATFULL (Continued)

L7 ANSWER 63 OF 65 USPATFULL
ACCESSION NUMBER: 75:11176 USPATFULL
TITLE: Anaesthetic steroids of the pregnane and 19-norpregnane series
INVENTOR(S): Phillipps, Gordon Hanley, Wembley, England
Newall, Christopher Earle, London, England
Ayres, Barry Edward, Amersham, England
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, Middlesex, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3869451	19750304
APPLICATION INFO.:	US 1971-197915	19711111 (5)
PRIORITY INFORMATION:	GB 1970-53911	19701112

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1677
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to steroids of the pregnane and 19-norpregnane series having anaesthetic properties and compositions containing them.
More particularly the present invention relates to such steroids having a variety of substituents in the 2.beta.-position, a 3.alpha.-hydroxy group and a 5.alpha.-hydrogen atom and esters and 20-ketals thereof. At the 11-position of such steriods is preferably either two hydrogen atoms or an oxo group. The compounds according to the invention may conveniently be prepared by reaction of an appropriate 2.alpha.,3.alpha.-epoxy-pregnane or 19-norpregnane with a reagent which introduces the desired 2.beta.-substituent and various modifications of the compound produced are described to produce compounds within the scope of the invention. The present invention provides compositions containing certain steroids of the pregnane and 19-norpregnane series and such compositions generally may be administered intravenously to induce anaesthesia, the invention providing methods of inducing anaesthesia.
IT **38689-90-6P**
(prepn. of)

L7 ANSWER 63 OF 65 USPATFULL (Continued)
RN 38689-90-6 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-2-methoxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 64 OF 65 USPATFULL
ACCESSION NUMBER: 72:39193 USPATFULL
TITLE: PROCESS FOR PREPARING 17.alpha.-HYDROXY-20-KETO AND 17.alpha.,21-DIHYDROXY-20-KETO PREGNANES AND DERIVATIVES AND INTERMEDIATES THEREOF
INVENTOR(S): Crabbe, Pierre, Mexico City, Mexico
Velarde, Esperanza, Mexico City, Mexico
PATENT ASSIGNEE(S): Syntex Corporation, Panama, Panama

	NUMBER	DATE
PATENT INFORMATION:	US 3681410	19720801
APPLICATION INFO.:	US 1970-62201	19700807 (5)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1969-854742, filed on 2 Sep 1969, now abandoned	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Gotts, Lewis
ASSISTANT EXAMINER: Love, Ethel G.
LEGAL REPRESENTATIVE: Merker, Evelyn K.
NUMBER OF CLAIMS: 25
LINE COUNT: 1282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New processes for preparing 17.alpha.-hydroxy-20-keto and 17.alpha.,21-dihydroxy-20-keto pregnanes and derivatives thereof, which compounds are useful as progestational and anti-inflammatory agents. The processes utilize the steps of converting a 17.alpha.-ethynyl-17.beta.-acyloxy steroid to the corresponding 17-vinylidene steroid with zinc in an ethylene glycol ether and oxidizing the 17-vinylidene steroid to form the corresponding product pregnanes. The novel 17-vinylidene compounds are useful as intermediates as herein described and are also useful anti-androgenic agents.
IT **35458-60-7P 35458-61-8P 36025-37-3P**
36025-39-5P 36025-45-3P 36025-53-3P
36025-59-9P
(prepn. of)
RN 35458-60-7 USPATFULL
CN Pregnan-20-one, 3-(acetyloxy)-17,21-dihydroxy-, (3.beta.,5.alpha.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 64 OF 65 USPATFULL (Continued)



RN 35458-61-8 USPATFULL
CN Pregnan-20-one, 3-(acetyloxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36025-37-3 USPATFULL
CN Pregnan-20-one, 9-fluoro-3,11,17,21-tetrahydroxy-, (3.beta.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 64 OF 65 USPATFULL (Continued)

RN 36025-39-5 USPATFULL
CN Pregnan-20-one, 3,21-bis(acetyloxy)-9-fluoro-11,17-dihydroxy-, (3.beta.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36025-45-3 USPATFULL
CN Pregnane-11,20-dione, 3-(acetyloxy)-17,21-dihydroxy-16-methyl-, (3.beta.,5.alpha.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36025-53-3 USPATFULL
CN Pregnan-20-one, 9-fluoro-3,11,17,21-tetrahydroxy-6-methyl-, (3.beta.,5.alpha.,6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 64 OF 65 USPATFULL (Continued)



RN 36025-59-9 USPATFULL
CN Pregnan-20-one, 21-[(3-chlorobenzoyl)oxy]-3,17-dihydroxy-6,16-dimethyl-, (3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 65 OF 65 USPATFULL

ACCESSION NUMBER:	72:39187 USPATFULL
TITLE:	PROCESS FOR THE PREPARATION OF 5-BROMO-6-FLUORO-STEROIDS
INVENTOR(S):	Wieske, Reinhold, Berlin, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of

	NUMBER	DATE
PATENT INFORMATION:	US 3681404	19720801
APPLICATION INFO.:	US 1970-23456	19700327 (5)
PRIORITY INFORMATION:	DE 1969-1916823	19690329

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: French, Henry A.
LEGAL REPRESENTATIVE: Millen, Raptes and White
NUMBER OF CLAIMS: 8
LINE COUNT: 242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 5-Bromo-6-fluoro steroids are produced by the bromine-fluorine addition to the double bond of a .DELTA..sup.5 -unsaturated steroid using an N-bromoacylamide or N-bromoimide and aqueous hydrogen fluoride. A novel steroid produced by the process is 6.beta.-fluoro-5.alpha.-bromo-3.beta.,17.beta.-dihydroxy-androstane.

IT 1176-85-8P
(prepn. of)
RN 1176-85-8 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-5-bromo-6-fluoro-3-hydroxy-16-methyl-, (3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> d his

     (FILE 'HOME' ENTERED AT 09:00:07 ON 19 NOV 1999)

     FILE 'REGISTRY' ENTERED AT 09:00:49 ON 19 NOV 1999
L1             STRUCTURE UPLOADED
L2              48 S L1
L3            1404 S L1 FULL
L4            1276 S L3 AND 1/NC

     FILE 'CAPLUS' ENTERED AT 09:02:21 ON 19 NOV 1999
L5              52 S L4/THU
L6               7 S L5 NOT PY>=1995

     FILE 'USPATFULL' ENTERED AT 09:03:29 ON 19 NOV 1999
L7              65 S L4
```

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1999:450892 CAPLUS
DOCUMENT NUMBER: 131:102428
TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: U.S., 28 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606

PRIORITY APPLN. INFO.: US 1995-467404 19950606
OTHER SOURCE(S): MARPAT 131:102428

AB Neuroactive steroids of formula I [R = H, NH2, thio, sulfinyl, sulfonyl, halo, alkoxy, alkyl, alkenyl, alkynyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, etc.; R2 = H, alkoxy, keto, Me2N; R3 = alkoxy, alkenyloxy, alkynyloxy; R4 = H, Me; R5 = H, absent; R6 = H, alkanoyl, etc.; R7 = H, halo, OH, alkoxy, etc.; R8 = H, halo; R9 = H, halo, alkyl, alkoxy, arylalkoxy, amino; R10 = H, halo, alkyl, OH, alkoxy, CN, etc.] are prepd. These derivs. are capable of acting at a recently identified site on the GABA receptor complex (GRC), thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.beta.-methoxy-5.beta.-androstan-3-one to give II. II protected 87.5% of mice injected with metrazol from convulsions.

IT 186264-74-4P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neuroactive steroids of androstane and pregnane series)

RN 186264-74-4 CAPLUS

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-24-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-27-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 162883-05-8P 186264-24-4P 186264-27-7P
186264-34-6P 186264-35-7P 186264-36-8P
186264-37-9P 186264-38-0P 186264-54-0P
186264-61-9P 186264-63-1P 186264-79-9P
186264-84-6P 186264-85-7P 186264-86-8P
186264-87-9P 203719-57-7P 230958-75-5P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neuroactive steroids of androstane and pregnane series)

RN 162883-05-8 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-35-7 CAPLUS
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-36-8 CAPLUS
CN Pyridinium, 4-[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-37-9 CAPLUS
CN Pyridinium, 4-[[(3.alpha.,5.alpha.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-61-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

Absolute stereochemistry.



RN 186264-38-0 CAPLUS
CN Pyridinium, 4-[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-54-0 CAPLUS

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-84-6 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-85-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-, (3.alpha.,5.beta.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 230958-75-5 CAPLUS
CN Pyridinium, 4-[[(2.beta.,3.beta.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



● I⁻

RN 186264-87-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203719-57-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1998:112239 CAPLUS
DOCUMENT NUMBER: 128:188632
TITLE: Use of GABA agonists and NMDA receptor antagonists for the treatment of migraine headache
INVENTOR(S): Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA; Lan, Nancy C.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805337	A1	19980212	WO 1997-US13430	19970731
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9739672	A1	19980225	AU 1997-39672	19970731
PRIORITY APPLN. INFO.:			US 1996-22937	19960801
			WO 1997-US13430	19970731

AB Methods are disclosed for treating or preventing migraine headache by administering to an animal a GABA receptor agonist (e.g. a neuroactive steroid) and/or an NMDA receptor antagonist (e.g. a dihydroquinoxaline deriv.). Also disclosed are pharmaceutical compns. and kits for the treatment or prevention of migraine headache.

IT 162883-05-8 186264-24-4 186264-27-7
186264-34-6 186264-35-7 186264-36-8
186264-37-9 186264-54-0 186264-61-9
186264-63-1 186264-74-4 186264-79-9
186264-84-6 186264-85-7 186264-86-8
186264-87-9 203716-90-9 203719-56-6
203719-57-7 203785-79-9 203785-83-5
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA agonists and NMDA receptor antagonists for migraine headache treatment)

RN 162883-05-8 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-24-4 CAPLUS
CN Pregnan-20-one,
3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-,
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-27-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-36-8 CAPLUS
CN Pyridinium,
4-[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-
methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I-

RN 186264-37-9 CAPLUS
CN Pyridinium,
4-[[(3.alpha.,5.alpha.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-
methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-35-7 CAPLUS
CN Pregnan-20-one,
3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-
, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



● I-

RN 186264-54-0 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 186264-61-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-74-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-85-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-84-6 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



● I⁻

RN 186264-87-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203716-90-9 CAPLUS
CN Pregnan-20-one, 21-(1H-benzimidazol-2-ylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 203719-56-6 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-, (3.alpha.,5.alpha.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203719-57-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 203785-79-9 CAPLUS
CN Pyridinium, 4-[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxy-19-norpregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 203785-83-5 CAPLUS
CN Pregnan-20-one, 21-(1H-benzimidazol-2-ylthio)-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:113460 CAPLUS
DOCUMENT NUMBER: 126:131695
TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN

CA 2223996	AA	19961219	CA 1996-2223996	19960606
AU 9661725	A1	19961230	AU 1996-61725	19960606
EP 837874	A2	19980429	EP 1996-919372	19960606

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI

CN 1190404	A	19980812	CN 1996-195360	19960606
BR 9608592	A	19990629	BR 1996-8592	19960606
JP 11507643	T2	19990706	JP 1996-502210	19960606
NO 9705608	A	19980206	NO 1997-5608	19971204
FI 9704448	A	19971205	FI 1997-4448	19971205
PRIORITY APPLN. INFO.:			US 1995-467404	19950606
			WO 1996-US10115	19960606

OTHER SOURCE(S): MARPAT 126:131695

AB Compds. of formula I [R = H, NH2, thio, sulfinyl, sulfonyl, halogen, alkoxy, alkyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.; R2 = H, OH, alkoxy, alkanoyloxy, carbalkoxy, keto, amino; R3 = H, alkoxy, alkenyloxy, etc.; R4 = H, alkyl; R5 = H, absent; R6 = H, alkanoyl, aminocarbonyl, alkoxycarbonyl; R7 = H, halogen, OH, alkoxy, alkanoyloxy, carbalkoxy; R8 = H, halogen; R9 = H, halogen, alkyl, alkoxy, arylalkoxy, amino; R10 = H, halogen, OH, alkyl, etc.] are prepd. as neuroactive prodrugs, due to their ability to modulate the GABAA receptor-chloride ionophore complex. These derivs. are capable of acting at a recently

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.beta.-methoxy-5.beta.-androstan-3-one to give II. II (10 mg/kg IP) protected 87.5% of mice injected with metrazol from convulsions.

IT 162883-05-8P 186264-27-7P 186264-74-4P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neuroactive androstanes and pregnanes)

RN 162883-05-8 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-27-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 CAPLUS
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-35-7 CAPLUS
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-74-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 186264-24-4P 186264-34-6P 186264-35-7P
186264-36-8P 186264-37-9P 186264-38-0P
186264-54-0P 186264-61-9P 186264-63-1P
186264-79-9P 186264-84-6P 186264-85-7P
186264-86-8P 186264-87-9P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of neuroactive androstanes and pregnanes)

RN 186264-24-4 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-,

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-36-8 CAPLUS
CN Pyridinium, 4-[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I-

RN 186264-37-9 CAPLUS
CN Pyridinium, 4-[[(3.alpha.,5.alpha.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



● I⁻

RN 186264-38-0 CAPLUS
CN Pyridinium, 4-[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

RN 186264-54-0 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI)

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-84-6 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-, (3.alpha.,5.beta.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



RN 186264-61-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-85-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-, (3.alpha.,5.beta.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

=> d ibib ab hitstr 1-7

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1995:298133 CAPLUS
DOCUMENT NUMBER: 122:64421
TITLE: Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
INVENTOR(S): Clark, Abbot F.; Southren, Aaron L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 4 pp. Cont. of U.S. Ser. No.399,349, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5358943	A	19941025	US 1993-12181	19930202
			US 1987-139227	19871229
PRIORITY APPLN. INFO.:			US 1989-399349	19890828

AB Pharmaceutical compns. useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compns. are disclosed. The compns. contain a combination of a glucocorticoid and tetrahydrocortisol. The tetrahydrocortisol serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compns. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical compn. contg. tetrahydrocorticoid to a patient receiving such therapy. A formulation including tetrahydrocortisol and dexamethasone is presented.

IT 53-02-1D, Tetrahydrocortisol, mixts. with glucocorticoids
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids, and ophthalmic pharmaceuticals contg. combination of tetrahydrocortisol with corticosteroid)

RN 53-02-1 CAPLUS
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1994:646593 CAPLUS
DOCUMENT NUMBER: 121:246593
TITLE: Anticonvulsant activity of neurosteroids: correlation with .gamma.-aminobutyric acid-evoked chloride current potentiation
AUTHOR(S): Kokate, Tushar G.; Svensson, Bjoern E.; Rogawski, Michael A.
CORPORATE SOURCE: Neuronal Excitability Section, National Institute Neurological Diseases and Stroke, Bethesda, MD, USA
SOURCE: J. Pharmacol. Exp. Ther. (1994), 270(3), 1223-9
CODEN: JPETAB; ISSN: 0022-3565
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Certain neurosteroids rapidly alter the excitability of neurons, in part by potentiating GABA-evoked chloride currents, and, like other GABA potentiating drugs, may have anticonvulsant activity. We compared the abilities of a series of isomeric metabolites of progesterone and deoxycorticosterone (3-hydroxy pregnane-20-ones and 3-hydroxy pregnane-21-ol-20-ones) to enhance GABA-evoked chloride currents in cultured hippocampal neurons with their abilities to protect against pentylenetetrazole (PTZ)-induced seizures in mice. Metabolites with 3-hydroxy in the .alpha.-position and 5-H in the .alpha.- or .beta.-configuration were highly effective at potentiating GABA-evoked chloride current and also showed potent anticonvulsant activity in the PTZ seizure test. The corresponding metabolites with hydroxyl groups in the 3.beta.-position were considerably less potent in enhancing GABA responses and were inactive in the PTZ test. All of the neurosteroids failed to protect against tonic hindlimb extension in the maximal electroshock test. 5.alpha.-Pregnane-3.alpha.,11.beta.,21-triol-20-one, a corticosterone metabolite reported to block voltage-dependent Ca2+ channels, was inactive in either of the anticonvulsant tests. At higher doses, neurosteroids effective in the PTZ test also produced motor impairment. Relative motor toxicity was lower (higher protective index) for compds. with the 5.alpha.-configuration than for their corresponding 5.beta.-epimers. The anticonvulsant profile of the neurosteroids resembled that of the benzodiazepine clonazepam. Although the anticonvulsant steroids had greater in vitro potencies than clonazepam, they were less potent in vivo, and they had lower protective indexes. We conclude that certain naturally occurring neurosteroid isomers are highly effective anticonvulsants and this activity is correlated with their ability to potentiate GABAA receptor responses. Although toxicity (sedation) may be an impediment to the clin. use of neurosteroids in seizure therapy, there is variation among analogs in the extent to which toxicity is produced at anticonvulsant doses.

IT **567-01-1**, 3.beta.,21-Dihydroxy-5.alpha.-pregnan-20-one
567-02-2, 3.alpha.,21-Dihydroxy-5.alpha.-pregnan-20-one
567-03-3, 3.alpha.,21-Dihydroxy-5.beta.-pregnan-20-one
600-63-5, 3.alpha.,11.beta.,21-Trihydroxy-5.alpha.-pregnan-20-one
800-10-2, 3.beta.,21-Dihydroxy-5.beta.-pregnan-20-one
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(anticonvulsant activity correlated with GABA-evoked chloride current potentiation in hippocampus)

RN 567-01-1 CAPLUS
CN Pregnan-20-one, 3,21-dihydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 567-02-2 CAPLUS
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 567-03-3 CAPLUS

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 600-63-5 CAPLUS
CN Pregnan-20-one, 3,11,21-trihydroxy-, (3.alpha.,5.alpha.,11.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 800-10-2 CAPLUS
CN Pregnan-20-one, 3,21-dihydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1994:621209 CAPLUS
DOCUMENT NUMBER: 121:221209
TITLE: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents
AUTHOR(S): Teicher, Beverly A.; Holden, Sylvia A.; Ara, Gulshan; Alvarez Sotomayor, Enrique; Huang, Zhen Dong; Chen, Ying Nan; Brem, Harold
CORPORATE SOURCE: Dana-Farber Cancer Institute, Boston, MA, 02115, USA
SOURCE: Int. J. Cancer (1994), 57(6), 920-5
CODEN: IJCNAW; ISSN: 0020-7136
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The ability of TNP-470, a synthetic analog of fumagillin which has been described as an anti-angiogenic agent, to potentiate cytotoxic cancer therapies was investigated in vivo in the murine FSaIIC fibrosarcoma and the Lewis lung carcinoma. TNP-470 was more toxic toward FSaIIC tumor cells from tumors treated in vivo than toward bone-marrow CFU-GM from the same animals. TNP-470 had a dose-modifying effect on the toxicity of cyclophosphamide toward FSaIIC tumor cells which amounted to an 8-fold increase in tumor-cell killing at a cyclophosphamide dose of 500 mg/kg. Treatment with TNP-470 and minocycline increased the permeability of the FSaII fibrosarcoma in vivo to the fluorescent dye Hoechst 33342 and increased the killing of both the bright and the dim tumor cells by cyclophosphamide. TNP-470, esp. in combination with minocycline, formed a highly effective modulator combination for treatment of the Lewis lung carcinoma with cytotoxic cancer therapies against primary and metastatic disease. The combination of TNP-470/minocycline and cyclophosphamide led to 40 to 50% long-term survivors in Lewis-lung-carcinoma-bearing animals. Our results indicate that the use of anti-angiogenic modulators in cancer therapy is a very promising area for further study.

IT 53-02-1
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytotoxic cancer therapies potentiation by TNP-470 alone and with other anti-angiogenic agents)

RN 53-02-1 CAPLUS
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1994:595111 CAPLUS
DOCUMENT NUMBER: 121:195111
TITLE: .beta.-cyclodextrin tetradecasulfate/tetrahydrocortiso 1 .+-. minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma
AUTHOR(S): Teicher, Beverly A.; Sotomayor, Enrique Alvarez; Huang, Zhen Dong; Ara, Gulshan; Holden, Sylvia; Khandekar, Vrinda; Chen, Ying-Nan
CORPORATE SOURCE: Jt. Cent. Radiat. Ther., Dana-Farber Cancer Inst., Boston, MA, 02115, USA
SOURCE: Cancer Chemother. Pharmacol. (1993), 33(3), 229-38
CODEN: CCPHDZ; ISSN: 0344-5704
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tetrahydrocortisol, .beta.-cyclodextrin tetradecasulfate, and minocycline used alone or in combination are not very cytotoxic toward EMT-6 mouse mammary tumor cells growing in monolayer. Tetrahydrocortisol (100 .mu.M, 24 h) and .beta.-cyclodextrin tetradecasulfate (100 .mu.M, 24 h) protected EMT-6 cells from the cytotoxicity of CDDP, melphalan, 4-hydroperoxycyclophosphamide, BCNU, and X-rays under various conditions of oxygenation and pH. Minocycline (100 .mu.M, 24 h) either had no effect upon or was additive with the antitumor alkylating agents or X-rays in cytotoxic activity toward the EMT-6 cells in culture. The combination of the three modulators either had no effect upon or was to a small degree protective against the cytotoxicity of the antitumor alkylating agents or X-rays. The Lewis lung carcinoma was chosen for primary tumor growth-delay studies and tumor lung-metastases studies. Tetrahydrocortisol and .beta.-cyclodextrin tetradecasulfate were given in a 1:1 molar ratio by continuous infusion over 14 days, and minocycline was given i.p. over 14 days, from day 4 to day 18 post tumor implantation. The combination of tetrahydrocortisol/.beta.-cyclodextrin tetradecasulfate diminished the tumor growth delay induced by CDDP and melphalan and produced modest increases in the tumor growth delay produced by cyclophosphamide and radiation. Minocycline co-treatment increased the tumor growth delay produced by CDDP, melphalan, radiation, bleomycin, and, esp. cyclophosphamide, where 4 of 12 animals receiving minocycline (14 .times. 5 mg/kg, days 4-18) and cyclophosphamide (3 .times. 150 mg/kg, days 7, 9, 11) were long-term survivors. The 3 modulators given in combination produced further increases in tumor growth delay with all of the cytotoxic therapies, and 5 of 12 of the animals treated with the 3-modulator combination and cyclophosphamide were long-term survivors. Although neither tetrahydrocortisol/.beta.-cyclodextrin tetradecasulfate, minocycline, nor the three modulator combination impacted the no. of lung metastases, there was a decrease in the no. of large lung metastases. Treatment with the cytotoxic therapies alone reduced the no. of lung metastases. Addn. of the modulators to treatment with the cytotoxic therapies resulted in a further redn. in the no. of lung metastases. These results indicate that agents that inhibit the breakdown of the extracellular matrix can be useful addns. to the treatment of solid tumors.

IT 53-02-1, Tetrahydrocortisol
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.-cyclodextrin tetradecasulfate/tetrahydrocortisol .+-. minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma)

RN 53-02-1 CAPLUS
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1986:39720 CAPLUS
DOCUMENT NUMBER: 104:39720
TITLE: Pharmaceutical compositions containing unilamellar liposomes
INVENTOR(S): Muntwyler, Rene; Hauser, Helmut
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 65 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 152379	A2	19850821	EP 1985-810050	19850211
EP 152379	A3	19861029		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ES 540372	A1	19860601	ES 1985-540372	19850213
CA 1246446	A1	19881213	CA 1985-474204	19850213
DK 8500685	A	19850816	DK 1985-685	19850214
AU 8538753	A1	19850822	AU 1985-38753	19850214
AU 588798	B2	19890928		
ZA 8501111	A	19850925	ZA 1985-1111	19850214
JP 60190710	A2	19850928	JP 1985-26616	19850215
			CH 1984-736	19840215

PRIORITY APPLN. INFO.:

AB Aq. pharmaceutical dispersions made of unilamellar liposomes contg. an amphipathic drug and a phospholipid are given. The amphipathic drugs are quaternary ammonium compds., compds. convertible into quaternary ammonium derivs. by salt formation, .alpha.-amino acids, phosphonic acid esters, etc. Thus, 50 mg soybean lecithin was added to 20.33 mg 1-isopropylamino-3-(2-pyrrol-1-ylphenoxy)propan-2-ol-HCl [99740-06-4] in 30 mL MeOH-CHCl3 (1:1) in a vial. The vial was rotated, and the film which formed was treated with 1.5 mL H2O to give a dispersion of unilamellar liposomes.

IT 14107-37-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(unilamellar liposome pharmaceutical compns. contg.)

RN 14107-37-0 CAPLUS
CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1976:441191 CAPLUS
DOCUMENT NUMBER: 85:41191
TITLE: Structure-activity relationships in steroidal anesthetics
AUTHOR(S): Phillipps, G. H.
CORPORATE SOURCE: Scot.
SOURCE: Mol. Mech. Gen. Anaesth., Glaxo Symp. (1974), Meeting
Date 1973, 32-47. Editor(s): Halsey, M. J.; Millar,
Ronald Alexander, Sutton, J. A. Churchill-Livingstone: London, Engl.
CODEN: 32Q1AP
DOCUMENT TYPE: Conference
LANGUAGE: English
AB The essential nature of an oxygen atom in the 3-position of hydroxysteroids and of the importance of the exact manner in which it projects from the A ring for anesthetic potency was studied in mice. Improved potency and decreased toxicity compared with alphaxalone [23930-19-0] was achieved with a no. of water sol. compds. related to the
pregnane-20-ones (I). These compds. gave instantaneous anesthesia and did
not show untoward effects.
IT **567-02-2 14107-37-0 23930-37-2**
38392-87-9 38601-29-5 51086-93-2
51086-95-4 51087-15-1
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(anesthetic activity of)
RN 567-02-2 CAPLUS
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 14107-37-0 CAPLUS
CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 38601-29-5 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 51086-93-2 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 23930-37-2 CAPLUS
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-87-9 CAPLUS
CN Glycine, N,N-diethyl-, (3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 51086-95-4 CAPLUS
CN Pregnane-11,20-dione, 21-(acetylthio)-3-hydroxy-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-15-1 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-[[[2-(4-morpholinyl)ethoxy]thioxomethyl]thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1975:558163 CAPLUS
DOCUMENT NUMBER: 83:158163
TITLE: Structure-activity relations in steroidal anesthetics
AUTHOR(S): Phillipps, G. H.
CORPORATE SOURCE: Org. Chem. Dep., Glaxo Res. Ltd., Greenford/Middlesex, Engl.
SOURCE: J. Steroid Biochem. (1975), 6(5), 607-13
CODEN: JSTBBK
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The introduction of double bonds and substituents into Alphaxalone [23930-19-0] modify its anesthetic activity, as detd. in mice, and these modifications are discussed with particular ref. to the conformation of the A-ring. A variety of side chains may be present at the 17.beta.-position. Some water-sol. steroids which show instantaneous induction of anesthesia are described.

IT 567-02-2 14107-37-0 23930-37-2
38601-29-5 51086-93-2 51086-95-4
51087-15-1 56857-38-6
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anesthetic activity of)

RN 567-02-2 CAPLUS
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 14107-37-0 CAPLUS
CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 23930-37-2 CAPLUS
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-29-5 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 51086-93-2 CAPLUS

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)

CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-95-4 CAPLUS
CN Pregnane-11,20-dione, 21-(acetylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-15-1 CAPLUS
CN Pregnane-11,20-dione,
3-hydroxy-21-[[[2-(4-morpholinyl)ethoxy]thioxomethyl]thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56857-38-6 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-[(1-pyrrolidinylacetyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ibib ab hitstr 1-65

L7 ANSWER 1 OF 65 USPATFULL

ACCESSION NUMBER: 1999:99389 USPATFULL
TITLE: Formulations and methods for providing prolonged local anesthesia
INVENTOR(S): Chasin, Mark, Manalapan, NJ, United States
Sackler, Richard, Greenwich, CT, United States
Burch, Ronald M., Wilton, CT, United States
Goldenheim, Paul, Wilton, CT, United States
Tigner, Joseph, New Milford, CT, United States
PATENT ASSIGNEE(S): Euro-Celtique, S.A., Luxembourg, Luxembourg (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5942241	19990824
	WO 9641616	19961227
APPLICATION INFO.:	US 1997-793861	19970616 (8)
	WO 1996-US10439	19960607
		19970616 PCT 371 date
		19970616 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1995-60000105	19950609

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Levy, Neil S.
LEGAL REPRESENTATIVE: Davidson, Davidson & Kappel, LLC
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 1918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

IT 547-77-3, Allotetrahydrocortisone
(formulations and methods for providing prolonged local anesthesia)

RN 547-77-3 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 65 USPATFULL (Continued)



L7 ANSWER 2 OF 65 USPATFULL

ACCESSION NUMBER: 1999:96496 USPATFULL
TITLE: Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States
Xia, Haiji, Foothill Ranch, CA, United States
Hogenkamp, Derk, Carlsbad, CA, United States
PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5939545	19990817
APPLICATION INFO.:	US 1997-887229	19970702 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-389820, filed on 14 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-346927, filed on 23 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-196919, filed on 14 Feb 1994, now abandoned	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Dees, Jose G.
ASSISTANT EXAMINER: Badio, Barbara
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.

IT 162882-76-0P 162882-80-6P 162882-89-5P
162882-90-8P 162882-92-0P 162882-98-6P
162883-05-8P 162883-10-5P 162883-28-5P
162883-38-7P 162883-85-4P
(prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)

RN 162882-76-0 USPATFULL
CN 19-Norpregnan-20-one, 3,21-dihydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162882-80-6 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162882-89-5 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3-ethynyl-3-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 65 USPATFULL (Continued)

RN 162882-90-8 USPATFULL
CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-ethynyl-3-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162882-92-0 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162882-98-6 USPATFULL
CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-3-(trifluoromethyl), (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162883-28-5 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162883-38-7 USPATFULL
CN Pregnan-20-one, 21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162883-05-8 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162883-10-5 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(methylsulfonyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162883-85-4 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-methoxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 567-03-3 2402-24-6 96611-83-5
117899-40-8 148346-37-6 162882-67-9
162883-26-3
(prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)

RN 567-03-3 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 2402-24-6 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 96611-83-5 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162882-67-9 USPATFULL
CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162883-26-3 USPATFULL
CN 19-Norpregnan-20-one, 3-hydroxy-21-methoxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 117899-40-8 USPATFULL
CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148346-37-6 USPATFULL
CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



IT 162883-49-0
(prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)
RN 162883-49-0 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



IT 162883-34-3P 162883-41-2P
(prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)
RN 162883-34-3 USPATFULL
CN Pregnan-20-one,
21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162883-41-2 USPATFULL
CN 19-Norpregnan-20-one,
21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 65 USPATFULL
ACCESSION NUMBER: 1999:81822 USPATFULL
TITLE: Neuroactive steroids of the androstane and pregnane series
INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States
Fick, David B., Mission Viejo, CA, United States
Hogenkamp, Derk J., Carlsbad, CA, United States
Lan, Nancy C., South Pasadena, CA, United States
PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5925630	19990720
APPLICATION INFO.:	US 1996-659192	19960606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-467404, filed on 6 Jun 1995
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Badio, Barbara
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 3047
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural Formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 =methyl), 19-norandrostanes, and norpregnanes (R.sub.4 =H).

IT 186264-39-1P 186264-40-4P 186264-51-7P
186264-62-0P 186264-74-4P 186264-76-6P
(prepn. of neuroactive steroids of androstane and pregnane series)

RN 186264-39-1 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(2-hydroxyethyl)thio]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 65 USPATFULL (Continued)

Absolute stereochemistry.



RN 186264-40-4 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(3-hydroxypropyl)thio]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-51-7 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(3-hydroxypropyl)sulfinyl]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 65 USPATFULL (Continued)

RN 186264-62-0 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-(4-nitrophenoxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-74-4 USPATFULL
CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-76-6 USPATFULL
CN Pregnan-20-one,
21-[(4-fluorophenyl)sulfonyl]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



IT 567-02-2P, 3.alpha.,21-Dihydroxy-5.alpha.-pregnan-20-one
567-03-3P 162883-05-8P 186264-24-4P
186264-27-7P 186264-31-3P 186264-33-5P
186264-34-6P 186264-35-7P 186264-41-5P
186264-42-6P 186264-52-8P 186264-53-9P
186264-54-0P 186264-61-9P 186264-63-1P
186264-64-2P 186264-65-3P 186264-66-4P
186264-67-5P 186264-79-9P 186264-81-3P
186264-84-6P 186264-85-7P 186264-87-9P
203719-57-7P
(prepn. of neuroactive steroids of androstane and pregnane series)

RN 567-02-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 567-03-3 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-27-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-31-3 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)

Absolute stereochemistry.



RN 162883-05-8 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 186264-24-4 USPATFULL
CN Pregnan-20-one,
3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-,
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-33-5 USPATFULL
CN Pregnan-20-one,
21-[(4-fluorophenyl)thio]-3-hydroxy-3-(methoxymethyl)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-35-7 USPATFULL
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-41-5 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-[(3-hydroxypropyl)thio]-2-propoxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-53-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-[(3-hydroxypropyl)sulfonyl]-2-propoxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-54-0 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-42-6 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-[(2-hydroxyethyl)thio]-, (3.alpha.,5.beta.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-52-8 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(3-hydroxypropyl)sulfonyl]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-61-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 186264-63-1 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-64-2 USPATFULL
CN Pregnan-20-one, 21-[4-(dimethylamino)phenoxy]-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-65-3 USPATFULL
CN Pregnan-20-one, 21-[[4-(dimethylamino)phenyl]thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-79-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-81-3 USPATFULL
CN Pregnan-20-one, 21-[(4-aminophenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-66-4 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-67-5 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[[4-(1-pyrrolidinyl)phenyl]sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-84-6 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-85-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-87-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203719-57-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



L7 ANSWER 4 OF 65 USPATFULL

ACCESSION NUMBER: 1999:24638 USPATFULL
TITLE: Compositions and methods for modulating growth of a tissue in a mammal
INVENTOR(S): Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5874419	19990223
APPLICATION INFO.:	US 1997-905612	19970804 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 20 -900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809, issued on 2 Feb 1993

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Prats, Francisco
LEGAL REPRESENTATIVE: Panitch Schwarze Jacobs & Nadel, P.C.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

L7 ANSWER 4 OF 65 USPATFULL (Continued)

IT 53-05-4
(prepn. of cyclodextrin conjugates with drugs to improve water soly.)
RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 65 USPATFULL

ACCESSION NUMBER: 1998:157488 USPATFULL
TITLE: Oligosaccharide-containing 14 aminosteroid compounds
and novel diastereoselective aminosteroid process chemistry
INVENTOR(S): Dybas, Paul Michael, Port Crane, NY, United States
Johnson, Roland Norman, Norwich, NY, United States
Muth, Randy Stuart, Poolville, NY, United States
Liu, Song, Norwich, NY, United States
Portlock, David Edward, Norwich, NY, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5849889	19981215
APPLICATION INFO.:	US 1997-802491	19970220 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-406833, filed on 20 Mar 1995, now abandoned which is a continuation of Ser. No. US 1993-126459, filed on 24 Sep 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Knode, Marian C.
ASSISTANT EXAMINER: Lee, Howard C.
LEGAL REPRESENTATIVE: McMahon, Mary Pat; Winter, William J.; Clark, Karen F.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 2245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to new 14-aminosteroids, pharmaceutical compositions containing the new compounds and methods of treatment for humans or other mammals afflicted with congestive heart failure.

IT 26520-64-9P
(prepn. of oligosaccharide-contg. 14-aminosteroid cardiovascular and inotropic agents and diastereoselective aminosteroid process chem.)

RN 26520-64-9 USPATFULL
CN Pregnan-20-one, 3-[(O-3,4-di-O-acetyl-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-3-O-acetyl-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-3-O-acetyl-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-14,21-dihydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 5 OF 65 USPATFULL (Continued)



L7 ANSWER 6 OF 65 USPATFULL

ACCESSION NUMBER: 1998:101671 USPATFULL
TITLE: Cytoskeletal active agents for glaucoma therapy
INVENTOR(S): Kaufman, Paul L., Madison, WI, United States
Geiger, Benjamin, Rehovot, Israel
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5798380	19980825
APPLICATION INFO.:	US 1996-604568	19960221 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.

IT 53-02-1
(glaucoma treatment with compds. causing perturbation of cell adhesions in trabecular meshwork)

RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 65 USPATFULL

ACCESSION NUMBER: 1998:72617 USPATFULL
TITLE: Prevention and treatment of ocular neovascularization
using angiostatic steroids
INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5770592	19980623
APPLICATION INFO.:	US 1997-895184	19970716 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-342524, filed on 21 Nov 1994, now patented, Pat. No. US 5679666 And Ser. No. US 1991-796169, filed on 22 Nov 1991, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Yeager, Sally
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and formulations for treating ocular neovascularization using angiostatic steroids are disclosed.

IT 68-60-0, Tetrahydrocortexolone
(glaucoma treatment with)

RN 68-60-0 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 8 OF 65 USPATFULL
ACCESSION NUMBER: 1998:64714 USPATFULL
TITLE: Methods of using steroid-polyanionic polymer-based conjugated targeted to vascular endothelial cells
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents the University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5762918	19980609	
	WO 9318793	19930930	
APPLICATION INFO.:	US 1994-307745	19941205	(8)
	WO 1993-US2619	19930322	
		19941205	PCT 371 date
		19941205	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-856018, filed on 23 Mar 1992, now patented, Pat. No. US 5474765
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Page, Thurman K.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention discloses new targeted conjugates for the delivery of a compound, and particularly, a steroid, to vascular endothelial cells. The conjugates comprise two components, preferably linked by a selectively-hydrolyzable bond, such as an acid-labile bond or enzyme-sensitive bond. The first component, a polyanionic polymer, and preferably, a polysulphated polymer such as a heparin-derivative, specifically directs the conjugate to vascular endothelial cells. The second component is a selected agent, such as a steroid, which exerts a specific effect on the target cell following its release. In particular, the present invention provides novel conjugated angiogenesis inhibitors, for use in the treatment of pathogenic conditions including cancer, arthritis, and diabetic blindness. An inhibitor comprising a heparin derivative and the anti-angiogenic steroid, cortisol, is herein shown to be markedly acid-labile, to suppress DNA synthesis and cell migration in human umbilical vein endothelial cells, to retard or abolish (depending pending on the route of injection) the vascularization of sponges in vivo and to retard lung tumor growth in mice by 65%. No adverse effects of the conjugate were detected, and equivalent treatments with a mixture of heparin plus cortisol were significantly less effective in all cases.

IT 53-02-1DP, Tetrahydrocortisol, heparin conjugate
53-05-4DP, Tetrahydrocortisone, heparin conjugate
68-42-8DP, Tetrahydrocorticosterone, heparin conjugate
68-60-0DP, Tetrahydro S, heparin conjugate
(prepn. of steroid-heparin conjugates as angiogenesis inhibitors)

RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68-42-8 USPATFULL
CN Pregnan-20-one, 3,11,21-trihydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68-60-0 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 65 USPATFULL
ACCESSION NUMBER: 1998:61630 USPATFULL
TITLE: Cyclodextrin compounds and methods of making and use thereof
INVENTOR(S): Joullie , Madeleine M., Philadelphia, PA, United States
Weisz, Paul B., State College, PA, United States
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5760015	19980602	
APPLICATION INFO.:	US 1995-416107	19950403	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809 And a continuation of Ser. No. US 1991-790592, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-434659, filed on 9 Nov 1989, now patented, Pat. No. US 5019562 which is a continuation of Ser. No. US 1989-295638, filed on 10 Jan 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-145407, filed on 19 Jan 1988, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fonda, Kathleen K.
LEGAL REPRESENTATIVE: Panitch Schwarze Jacobs & Nadel, P.C
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides polyanionic, substituted CDs having cellular growth modulating activity. The invention further provides CDs having anionic groups on one side of the CD molecule. Therapeutic methods for using, as well as methods of making the CD compounds of the invention, are also disclosed herein.

L7 ANSWER 9 OF 65 USPATFULL (Continued)
IT 53-05-4
(prepn. of cyclodextrin conjugates with drugs to improve water soly.)
RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 65 USPATFULL
ACCESSION NUMBER: 1998:7175 USPATFULL
TITLE: Oligosaccharide-containing 14-aminosteroid compounds and novel diastereoselective aminosteroid process chemistry
INVENTOR(S): Dybas, Paul Michael, Port Crane, NY, United States
Johnson, Roland Norman, Norwich, NY, United States
Muth, Randy Stuart, Poolville, NY, United States
Liu, Song, Norwich, NY, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5710259	19980120
APPLICATION INFO.:	US 1995-459911	19950602 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-406833, filed on 20 Mar 1995, now abandoned which is a continuation of Ser. No. US 1993-126459, filed on 24 Sep 1993, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kight, John	
ASSISTANT EXAMINER:	Lee, Howard C.	
LEGAL REPRESENTATIVE:	McMahon, Mary P.; Clark, Karen F.; Rasser, Jacobus C.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2072	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to oligosaccharide-containing 14-aminosteroid compounds and the pharmaceutically-acceptable acid salts or esters thereof of the general formula: ##STR1## wherein a) R.sub.1 is

(i) COOR.sub.5, where

R.sub.5 is hydrogen, a 1-6 carbon lower alkyl; a 1-6 carbon lower alkyl substituted by an amino group; an arylalkyl or heteroarylalkyl or a carbocyclic ring, or

(ii) CHR.sub.6 OH, where

R.sub.6 is a hydrogen atom or 1-6 carbon lower alkyl group, or

(iii) COR'", where R'" is hydrogen; 1-6 carbon lower alkyl; 1-6 carbon lower alkyl substituted amino; amino or dialkylamino; and

L7 ANSWER 10 OF 65 USPATFULL (Continued)
b) R.sub.2 is --NR.sub.7 R.sub.8, where

R.sub.7 and R.sub.8, which may be the same or different, are hydrogen atoms or a 1-6 carbon lower alkyl; and

c) R.sub.3 is an oligosaccharide sugar residue; and

d) R.sub.4 is

(i) OH, or

(ii) H, or

(iii) OR.sub.13, where

R.sub.13 is a monosaccharide sugar residue; acetoxy; benzoxy; arylalkyl or heteroarylalkyl; and

e) Z is

(i) --CH--, where

a and b are single bonds, or

(ii) .dbd.C, where

either a or b is a double bond.

The present invention also relates to a process for introducing an amino group at the 14-position on a steroid nucleus wherein said amino group is diasteroselectively introduced onto the 14-position of the steroid nucleus via an iodoisocyanate addition comprising the steps of:

a) adding the iodoisocyanate to the 14-15 position double bond on the steroid nucleus; and

b) dehalogenation; and

c) isocyanate conversion to the amine moiety on the 14-position of the steroid nucleus.
IT 26520-64-9P
(prepn. of oligosaccharide-contg. 14-aminosteroid cardiovascular and inotropic agents and diastereoselective aminosteroid process chem.)
RN 26520-64-9 USPATFULL
CN Pregnan-20-one, 3-[(O-3,4-di-O-acetyl-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-3-O-acetyl-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-3-O-acetyl-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-14,21-dihydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI)

L7 ANSWER 10 OF 65 USPATFULL (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 11 OF 65 USPATFULL
ACCESSION NUMBER: 97:118036 USPATFULL
TITLE: Angiostatic steroids and methods and compositions for
controlling ocular hypertension
INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
Conrow, Raymond E., Fort Worth, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5698545	19971216
APPLICATION INFO.:	US 1996-643387	19960506 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-349342, filed on 2 Dec 1994, now abandoned which is a continuation of Ser. No. US 1992-941485, filed on 8 Sep 1992, now patented, Pat. No. US 5371078 which is a continuation-in-part of Ser. No. US 1990-559123, filed on 27 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-419226, filed on 10 Oct 1989, now abandoned which is a continuation of Ser. No. US 1988-264918, filed on 31 Oct 1988, now patented, Pat. No. US 4876250
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Prior, Kimberly J.
LEGAL REPRESENTATIVE: Yeager, Sally
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 695
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating ocular hypertension, including controlling the ocular hypertension associated with primary open angle glaucoma, are disclosed. In addition, the combination of the compounds with glucocorticoids for the prevention of elevated IOP during the treatment of inflammation is disclosed.
IT 68-60-0, Tetrahydrocortexolone
(glaucoma treatment with)
RN 68-60-0 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 12 OF 65 USPATFULL
ACCESSION NUMBER: 97:99410 USPATFULL
TITLE: Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
INVENTOR(S): Ashton, Paul, Boston, MA, United States
Smith, Thomas J., Weston, MA, United States
Glavinos, Peter G., Doylestown, PA, United States
Conklin, Jr., John D., Lexington, KY, United States
Crooks, Peter A., Lexington, KY, United States
Riggs, Robert M., Birmingham, AL, United States
Cynkowski, Tadeusz, Lexington, KY, United States
Cynkowska, Grazyna, Lexington, KY, United States
PATENT ASSIGNEE(S): University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5681964	19971028
APPLICATION INFO.:	US 1994-318160	19941005 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-162388, filed on 7 Dec 1993, now abandoned which is a continuation of Ser. No. US 1993-16179, filed on 11 Feb 1993, now abandoned which is a continuation of Ser. No. US 1990-601644, filed on 23 Oct 1990, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Killos, Paul J.
LEGAL REPRESENTATIVE: Lowe, Price, LeBlanc & Becker
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1180
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Prodrugs containing an active drug molecule linked to a polyethylene glycol group, and a method of use thereof are described. Exemplary soluble ester prodrugs contain naproxen, triamcinolone acetonide, gancyclovir, taxol, cyclosporin, dideoxyinosine, trihydroxy steroids, and flurbiprofen molecules linked to polyethylene glycol (PEG) groups. Pharmaceutical compositions containing these prodrugs, and a method of using these esters for treating disease states or symptoms are also described.
IT 68-60-0
(prepn. of permeable, non-irritating prodrugs of nonsteroidal and steroidal agents)
RN 68-60-0 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 198209-75-5P 198209-77-7P 198209-79-9P
198209-81-3P 198209-83-5P 198209-85-7P
(prepn. of permeable, non-irritating prodrugs of nonsteroidal and steroidal agents)
RN 198209-75-5 USPATFULL
CN Pregnan-20-one, 3,21-bis[(10,10-dimethyl-1-oxo-9,9-diphenyl-2,5,8-trioxa-9-silaundec-1-yl)oxy]-17-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 198209-77-7 USPATFULL
CN Pregnan-20-one, 3-[(10,10-dimethyl-1-oxo-9,9-diphenyl-2,5,8-trioxa-9-silaundec-1-yl)oxy]-17,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 12 OF 65 USPATFULL (Continued)

Absolute stereochemistry.



RN 198209-79-9 USPATFULL
CN Pregnan-20-one, 21-[(10,10-dimethyl-1-oxo-9,9-diphenyl-2,5,8-trioxa-9-silaundec-1-yl)oxy]-3,17-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198209-81-3 USPATFULL
CN Pregnan-20-one,
3,21-bis[(16,16-dimethyl-1-oxo-15,15-diphenyl-2,5,8,11,14-pentaoxa-15-silaheptadec-1-yl)oxy]-17-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 12 OF 65 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B



RN 198209-85-7 USPATFULL
CN Pregnan-20-one, 21-{(16,16-dimethyl-1-oxo-15,15-diphenyl-2,5,8,11,14-pentaoxa-15-silaheptadec-1-yl)oxy]-3,17-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 12 OF 65 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 198209-83-5 USPATFULL
CN Pregnan-20-one, 3-[(16,16-dimethyl-1-oxo-15,15-diphenyl-2,5,8,11,14-pentaoxa-15-silaheptadec-1-yl)oxy]-17,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 12 OF 65 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B



IT 198209-87-9P 198209-89-1P 198209-91-5P
198209-93-7P 198209-95-9P 198209-97-1P
(prepn. of permeable, non-irritating prodrugs of nonsteroidal and steroidal agents)
RN 198209-87-9 USPATFULL
CN Pregnan-20-one,
17-hydroxy-3,21-bis[[[2-(2-hydroxyethoxy)ethoxy]carbonyl]oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 12 OF 65 USPATFULL (Continued)

PAGE 1-B



RN 198209-89-1 USPATFULL
CN Pregnan-20-one,
17,21-dihydroxy-3-[[[2-(2-hydroxyethoxy)ethoxy]carbonyl]ox
y]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198209-91-5 USPATFULL
CN Pregnan-20-one,
3,17-hydroxy-21-[[[2-(2-hydroxyethoxy)ethoxy]carbonyl]oxy]-
, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 12 OF 65 USPATFULL (Continued)
CN Pregnan-20-one, 17,21-dihydroxy-3-[(13-hydroxy-1-oxo-2,5,8,11-
tetraoxatridec-1-yl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 198209-97-1 USPATFULL
CN Pregnan-20-one,
3,17-hydroxy-21-[(13-hydroxy-1-oxo-2,5,8,11-tetraoxatridec-
1-yl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 12 OF 65 USPATFULL (Continued)
RN 198209-93-7 USPATFULL
CN Pregnan-20-one, 17-hydroxy-3,21-bis[(13-hydroxy-1-oxo-2,5,8,11-
tetraoxatridec-1-yl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

RN 198209-95-9 USPATFULL

L7 ANSWER 12 OF 65 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B

L7 ANSWER 13 OF 65 USPATFULL
ACCESSION NUMBER: 97:96861 USPATFULL
TITLE: Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5679666	19971021
APPLICATION INFO.:	US 1994-342524	19941121 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-796169, filed on 22 Nov 1991, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Yeager, Sally
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and formulations for treating ocular neovascularization using angiostatic steroids are disclosed.
IT 68-60-0, Tetrahydrocortexolone
(glaucoma treatment with)
RN 68-60-0 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 13 OF 65 USPATFULL (Continued)

L7 ANSWER 14 OF 65 USPATFULL
ACCESSION NUMBER: 97:41865 USPATFULL
TITLE: Method, compositions, and compounds for modulating brain excitability
INVENTOR(S): Gee, Kelvin W., Irvine, CA, United States
Bolger, Michael B., Los Alamitos, CA, United States
Lan, Nancy C., South Pasadena, CA, United States
PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 35517	19970520
	US 5120723	19920609 (Original)
APPLICATION INFO.:	US 1992-980377	19921123 (7)
	US 1990-521724	19900510 (Original)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned
DOCUMENT TYPE: Reissue
PRIMARY EXAMINER: Tsang, Cecilia
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid/benzodiazepine receptor-chloride ionpore (GBR) complex.
IT 567-02-2
(anticonvulsant and anxiolytic)
RN 567-02-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 14 OF 65 USPATFULL (Continued)



L7 ANSWER 15 OF 65 USPATFULL
ACCESSION NUMBER: 97:3830 USPATFULL
TITLE: Substituted 2.beta.-morpholino-androstane derivatives
INVENTOR(S): Campbell, Alexander C., Falkirk, Scotland
PATENT ASSIGNEE(S): Akzo Nobel N.V., Arnhem, Netherlands (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5593983	19970114
APPLICATION INFO.:	US 1994-347974	19941201 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1993-309663	19931202

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Grumbling, Matthew V.
LEGAL REPRESENTATIVE: Gormley, Mary E.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,2
LINE COUNT: 1442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is related to substituted 2.beta.-morpholino-androstane derivatives, bonded at their 2.beta.-position to the nitrogen of a group of formula I ##STR1## wherein R represents one to four substituents, each one independently selected from (1-4C) alkyl, phenyl and benzyl, or two at the same carbon atom being together --(CH.sub.2).sub.n -- wherein n is 2-6; and Y is O or S, or a pharmaceutically acceptable salt thereof. These steroids are very potent intravenous anaesthetics. The compounds have fast onset times and ideal `sleep duration` vs. `recovery to full coordination` profiles.

IT **167947-21-9P**
(prepn. of 2.beta.-morpholinoandrostanes as anesthetics)
RN 167947-21-9 USPATFULL
CN Pregnan-20-one, 2-(2,2-dimethyl-4-morpholinyl)-3,21-dihydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 15 OF 65 USPATFULL (Continued)



RN 167947-17-3 USPATFULL
CN Pregnane-11,20-dione, 2-(2,2-dimethyl-4-morpholinyl)-3,21-dihydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167947-23-1 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 15 OF 65 USPATFULL (Continued)



IT **167946-99-8P 167947-00-4P 167947-17-3P 167947-23-1P 167947-78-6P 167947-79-7P**
(prepn. of 2.beta.-morpholinoandrostanes as anesthetics)
RN 167946-99-8 USPATFULL
CN Pregnane-11,20-dione, 21-(acetylthio)-2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167947-00-4 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 15 OF 65 USPATFULL (Continued)
RN 167947-78-6 USPATFULL
CN Pregnan-20-one, 2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-21-thiocyanato-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167947-79-7 USPATFULL
CN Pregnane-11,20-dione, 2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-21-thiocyanato-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **167947-07-1P 167947-08-2P 167947-22-0P**
(prepn. of 2.beta.-morpholinoandrostanes as anesthetics)
RN 167947-07-1 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.beta.,5.alpha.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 15 OF 65 USPATFULL (Continued)



RN 167947-08-2 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-[[(4-methylphenyl)sulfonyl]oxy]-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167947-22-0 USPATFULL
CN Pregnan-20-one, 2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-21-[(methylsulfonyl)oxy]-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 15 OF 65 USPATFULL (Continued)



L7 ANSWER 16 OF 65 USPATFULL

ACCESSION NUMBER: 97:1455 USPATFULL
TITLE: Methods, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
INVENTOR(S): Bolger, Michael B., Los Alamitos, CA, United States
Gee, Kelvin W., Irvine, CA, United States
Lan, Nancy C., South Pasadena, CA, United States
Purdy, Robert H., La Jolla, CA, United States
Mirsadeghi, Seid, Rolling Hills, CA, United States
Tahir, Syed Hasan, Edmonton, Canada
Belelli, Delia, Kingsbarns by St. Andrews, Scotland
PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5591733	19970107
APPLICATION INFO.:	US 1993-101497	19930802 (8)

DISCLAIMER DATE: 20100803
RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-745216, filed on 13 Aug 1991, now patented, Pat. No. US 5232917 which is a continuation-in-part of Ser. No. US 1990-521724, filed on 10 May 1990, now patented, Pat. No. US 5120723 which is a continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tsang, Cecilia
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 129
EXEMPLARY CLAIM: 1
LINE COUNT: 5060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex.
IT 567-02-2
(anticonvulsant and anxiolytic)
RN 567-02-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 16 OF 65 USPATFULL (Continued)



L7 ANSWER 17 OF 65 USPATFULL
ACCESSION NUMBER: 96:77773 USPATFULL
TITLE: Regulating neuropeptide hormone secretion
INVENTOR(S): Jackson, Meyer B., 3568 Tallyho La., Madison, WI, United States 53705

	NUMBER	DATE
PATENT INFORMATION:	US 5550120	19960827
APPLICATION INFO.:	US 1995-415741	19950403 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-109683, filed on 20 Aug 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Lankford, L. Blaine
LEGAL REPRESENTATIVE: Gulbrandsen, Carl E.Stroud, Stroud, Willink, Thompson & Howard
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are described for regulating neuropeptide secretion to alleviate premature labor, hypertension, fluid imbalance, and risk of heart disease: using neuroactive steroids targeted for a newly-identified site of action in the nerve terminals of neurosecretory neurons. The steroids 17 betaestradiol and dehydroepiandrosterone increase the release of neuropeptide hormones such as oxytocin and vasopressin. Pregnalone derivatives decrease the release of the same hormones.

IT 14107-37-0, 3.alpha.,21-Dihydroxy-5.alpha.-pregnane-11,20-dione (pharmacol. of vasopressin and oxytocin secretion-inhibiting steroids)
RN 14107-37-0 USPATFULL
CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 65 USPATFULL (Continued)



L7 ANSWER 18 OF 65 USPATFULL
ACCESSION NUMBER: 96:43650 USPATFULL
TITLE: Method for treating Kaposi's sarcoma and blocking or inhibiting vascular permeability
INVENTOR(S): Nakamura, Shuji, Pasadena, CA, United States
Gallo, Robert C., Bethesda, MD, United States
Osada, Yasuaki, Tokyo, Japan
Sakurada, Shinsaku, Tokyo, Japan
Tanaka, Noriko G., Tokyo, Japan
Salahuddin, Syed Z., Pasadena, CA, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)
Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5518999	19960521
APPLICATION INFO.:	US 1994-336612	19941109 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-810420, filed on 20 Dec 1991, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method for arresting or inhibiting the growth of cells in Kaposi's Sarcoma lesions and a method for arresting or inhibiting the growth of the Kaposi's Sarcoma lesions, said methods comprising contacting the cells in the lesions with an effective amount of SP-PG, a naturally occurring sulfated polysaccharide-peptidoglycan produced by a specific species of the bacterium Arthrobacter, AT-25. The invention is also directed to blocking or inhibiting the activity of cellular vascular permeability factor(s), which comprises contacting vascular cells with an effective amount of SP-PG. In one embodiment, there is provided a method for blocking or inhibiting increased vascular permeability (and resulting edema) in diseases and disorders in which the increased vascular permeability contributes to the pathology, for example, in Kaposi's Sarcoma, tumorigenesis, inflammation, diabetic retinopathy, etc. Increased effectiveness is obtained when SP-PG is combined with cortisone or a cortisone derivative, such as hydrocortisone or tetrahydrocortisone.

IT 53-05-4, Tetrahydrocortisone (cellular vascular permeability factor in vascular cells inhibition with sulfated polysaccharide-peptidoglycan SP-PG in combination with)
RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 18 OF 65 USPATFULL (Continued)



L7 ANSWER 19 OF 65 USPATFULL
ACCESSION NUMBER: 95:110215 USPATFULL
TITLE: Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
PATENT ASSIGNEE(S): UT SW Medical CTR at Dallas, Dallas, TX, United States
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5474765	19951212
APPLICATION INFO.:	US 1992-856018	19920323 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kishore, Gollamudi
ASSISTANT EXAMINER: Kulkosky, Peter F.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses new targeted conjugates for the delivery of a compound, and particularly, a steroid, to vascular endothelial cells. The conjugates comprise two components, preferably linked by a selectively-hydrolyzable bond, such as an acid-labile bond or enzyme-sensitive bond. The first component, a polyanionic polymer, and preferably, a polysulphated polymer such as a heparin-derivative, specifically directs the conjugate to vascular endothelial cells. The second component is a selected agent, such as asteroid, which exerts a specific effect on the target cell following its release. In particular, the present invention provides novel conjugated angiogenesis inhibitors, for use in the treatment of pathogenic conditions including cancer, arthritis, and diabetic blindness. An inhibitor comprising a heparin derivative and the anti-angiogenic steroid, cortisol, is herein shown to be markedly acid-labile, to suppress DNA synthesis and cell migration in human umbilical vein endothelial cells, to retard or abolish (depending on the route of injection) the vascularization of sponges in vivo and to retard lung tumor growth in mice by 65%. No adverse effects of the conjugate were detected, and equivalent treatments with a mixture of heparin plus cortisol were significantly less effective in all cases.

L7 ANSWER 19 OF 65 USPATFULL (Continued)



L7 ANSWER 19 OF 65 USPATFULL (Continued)
IT 53-02-1D, Tetrahydrocortisol, conjugates with anionic polymers
53-05-4D, Tetrahydrocortisone, conjugates with anionic polymers
68-42-8D, Tetrahydrocorticosterone, conjugates with anionic polymers
(for targeting to vascular endothelium)
RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68-42-8 USPATFULL
CN Pregnan-20-one, 3,11,21-trihydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 20 OF 65 USPATFULL
ACCESSION NUMBER: 95:71350 USPATFULL
TITLE: Methods and compositions for providing analgesia and enhanced anesthesia
INVENTOR(S): Bukusoglu, Cuneyt, 125 Old Mill Rd., Shrewsbury, MA, United States 01545
Thalhammer, Johann G., 398 Central St., Framingham, MA, United States 01701
Krieger, Neil R., 23 Lila Rd., Jamaica Plain, MA, United States 02130

	NUMBER	DATE
PATENT INFORMATION:	US 5439900	19950808
APPLICATION INFO.:	US 1993-23793	19930225 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Dees, Jose G.
ASSISTANT EXAMINER: Conrad, III, Joseph M.
LEGAL REPRESENTATIVE: Bromberg & Sunstein
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 697
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel method for preparing a subject for surgery by administering to said subject a composition which contains at least one steroid, an alcohol and a vehicle which is distinct from said alcohol. It has been discovered that there is a synergistic effect between the steroid and the alcohol which increases the anesthetic effect and the analgesic effect and shortens recovery times.
IT 567-03-3 800-10-2
(steroid and alc. combinations for providing analgesia and enhanced anesthesia for surgery)
RN 567-03-3 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 20 OF 65 USPATFULL (Continued)



RN 800-10-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 21 OF 65 USPATFULL (Continued)
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 21 OF 65 USPATFULL
ACCESSION NUMBER: 95:64955 USPATFULL
TITLE: Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
INVENTOR(S): Collins, Delwood C., Lexington, KY, United States
Gagliardi, Antonio, Lexington, KY, United States
Bhattacharyya, Anjan, Lexington, KY, United States
PATENT ASSIGNEE(S): The University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5434185	19950718
APPLICATION INFO.:	US 1993-61477	19930517 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: Weddington, K.
LEGAL REPRESENTATIVE: Lowe, Price, LeBlanc & Becker
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 776
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Aurintricarboxylic acid has potent anti-angiogenic activity and may be used for new therapeutic approaches for diseases of neovascularization including the treatment of solid tumors, diabetic retinopathy and arthritis, among others.
IT 53-02-1, Tetrahydrocortisol 68-60-0, Tetrahydrocortexolone
(aurintricarboxylic acid and analogs with anti-angiogenic activity)
RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68-60-0 USPATFULL

L7 ANSWER 22 OF 65 USPATFULL
ACCESSION NUMBER: 95:43238 USPATFULL
TITLE: 21-chloro-pregnane derivative
INVENTOR(S): Campbell, Alexander C., Falkirk, Scotland
PATENT ASSIGNEE(S): Akzo N.V., Arnhem, Netherlands (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5416079	19950516
APPLICATION INFO.:	US 1993-96327	19930722 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1992-306697	19920722

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rizzo, Nicholas
LEGAL REPRESENTATIVE: Blackstone, William M.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 3
LINE COUNT: 158
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is related to a 21-chloro-pregnane derivative of the formula ##STR1## or pharmaceutically acceptable salts thereof. The compound has intravenous anaesthetic activity, short onset time and high potency.
IT 156685-97-1P
(prepn. and hydrolysis of, in prepn. of anesthetic)
RN 156685-97-1 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 156685-98-2P 156685-99-3P
(prepn. of, as anesthetic intermediate)
RN 156685-98-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-2-(4-morpholinyl)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 22 OF 65 USPATFULL (Continued)



RN 156685-99-3 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-[(methylsulfonyl)oxy]-2-(4-morpholinyl)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 23 OF 65 USPATFULL (Continued)
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 23 OF 65 USPATFULL

ACCESSION NUMBER:	95:34174 USPATFULL
TITLE:	Ophthalmic composition
INVENTOR(S):	Clark, Abbot F., Arlington, TX, United States
PATENT ASSIGNEE(S):	Alcon Laboratories, Inc., Ft. Worth, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5407926	19950418
APPLICATION INFO.:	US 1992-966118	19921023 (7)
DISCLAIMER DATE:	20070731	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-555692, filed on 23 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-399351, filed on 28 Aug 1989, now patented, Pat. No. US 4945089 which is a continuation of Ser. No. US 1987-139222, filed on 29 Dec 1987, now abandoned And Ser. No. US 1989-419226, filed on 10 Oct 1989, now abandoned which is a continuation of Ser. No. US 1988-264918, filed on 31 Oct 1988, now patented, Pat. No. US 4876250	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fay, Zohreh	
LEGAL REPRESENTATIVE:	Cheng, Julie J. L.; Brown, Gregg C.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	477	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and an angiostatic steroid. The angiostatic steroid substantially prevents any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent anti-inflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure.

IT 68-60-0, Tetrahydrocortexolone
(glaucoma treatment with)
RN 68-60-0 USPATFULL

L7 ANSWER 24 OF 65 USPATFULL

ACCESSION NUMBER:	95:34082 USPATFULL
TITLE:	Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
INVENTOR(S):	Dubler, Robert E., Gurnee, IL, United States Frintner, Mary P., Elk Grove, IL, United States Grote, Jonathan, Grayslake, IL, United States Hadley, Gregg A., St. Louis, MO, United States Hawksworth, David J., Vernon Hills, IL, United States Hopkins, Hal D., Chicago, IL, United States Nam, Daniel S., Lake Elsinore, CA, United States Ungemach, Frank S., Lake Villa, IL, United States Wray, Larry K., Highland Park, IL, United States
PATENT ASSIGNEE(S):	Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5407834	19950418
APPLICATION INFO.:	US 1992-831762	19920427 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-529988, filed on 29 May 1990, now patented, Pat. No. US 5155212 which is a continuation-in-part of Ser. No. US 1986-866193, filed on 21 May 1986, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kim, Kay K. A.	
LEGAL REPRESENTATIVE:	Pope, Lawrence S.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1662	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.

IT 53-05-4, Tetrahydrocortisone
(phencyclidine fluorescence polarization immunoassay crossreactivity to)
RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA

L7 ANSWER 24 OF 65 USPATFULL (Continued)
INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 25 OF 65 USPATFULL
ACCESSION NUMBER: 95:15936 USPATFULL
TITLE: Process for the production of 4-pregnene-3,20-dione and its derivatives using mycobacterium NRRL B-3805
INVENTOR(S): Weber, Alfred, Berlin, Germany, Federal Republic of
Kennecke, Mario, Berlin, Germany, Federal Republic of
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5391484	19950221	
	WO 9203571	19920305	
APPLICATION INFO.:	US 1992-861807	19920618	(7)
	WO 1991-DE620	19910730	
		19920618	PCT 371 date
		19920618	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1990-4026464	19900818

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Lankford, L. Blaine
LEGAL REPRESENTATIVE: Millen, White, Zelano & Branigan
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for the production of 4-pregnene-3,20-dione and its derivatives of general formula I ##STR1## in which R.sub.1 means a hydrogen atom, a fluorine atom or a methyl group,

R.sub.2 represents a hydrogen atom or a hydroxy group, and

R.sub.3 and R.sub.4 together symbolize a carbon-carbon bond or

R.sub.3 represents a hydrogen atom, a hydroxy group or an alkanoyloxy group with up to 6 carbon atoms and

R.sub.4 means a hydrogen atom or a methyl group, is described, which is characterized in that a pregnane derivative of general formula II ##STR2## in which R.sub.1, R.sub.3 and R.sub.4 have the above-mentioned meaning, symbolizes a single bond or a double bond,

R.sub.5 represents a hydrogen atom, a hydroxy group or an alkanoyloxy

L7 ANSWER 25 OF 65 USPATFULL (Continued)
group with at most 6 carbon atoms and

R.sub.6 means a hydrogen atom or an alkanoyl group with at most 6 carbon atoms, is fermented with a bacterial culture of species Mycobacterium spec. NRRL B-3805.
IT 10147-45-2
(pregnenediones manuf. from, with Mycobacterium)
RN 10147-45-2 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 26 OF 65 USPATFULL
ACCESSION NUMBER: 94:106777 USPATFULL
TITLE: Angiostatic steroids and methods and compositions for controlling ocular hypertension
INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
Conrow, Raymond E., Fort Worth, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5371078	19941206	
APPLICATION INFO.:	US 1992-941485	19920908	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-559123, filed on 27 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-419226, filed on 10 Oct 1989, now abandoned which is a continuation of Ser. No. US 1988-264918, filed on 31 Oct 1988, now patented, Pat. No. US 4876250
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Kestler, Kimberly J.
LEGAL REPRESENTATIVE: Yeager, Sally
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 744
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating ocular hypertension, including controlling the ocular hypertension associated with primary open angle glaucoma, are disclosed. In addition, the combination of the compounds with glucocorticoids for the prevention of elevated IOP during the treatment of inflammation is disclosed.
IT 53-02-1, Tetrahydrocortisol
(prepn. of angiostatic steroids for controlling ocular hypertension)
RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 26 OF 65 USPATFULL (Continued)



IT 149916-71-2P 150213-49-3P
(prepn. of angiostatic steroids for controlling ocular hypertension)
RN 149916-71-2 USPATFULL
CN Pregnan-20-one, 21-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-3,11,17-trihydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150213-49-3 USPATFULL
CN Pregnan-20-one, 21-{[(1,1-dimethylethyl)diphenylsilyl]oxy}-11,17-dihydroxy-3-(1H-imidazol-1-ylthioxomethoxy)-, (3.alpha.,5.beta.,11.beta.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 26 OF 65 USPATFULL (Continued)



L7 ANSWER 27 OF 65 USPATFULL

ACCESSION NUMBER: 94:102232 USPATFULL
TITLE: Modulation of receptor-mediated ion transport
INVENTOR(S): Farb, David H., Cambridge, MA, United States
PATENT ASSIGNEE(S): Trustees of Boston University, Boston, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5366968	19941122
APPLICATION INFO.:	US 1993-7068	19930121 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-758129, filed on 12 Sep 1991, now patented, Pat. No. US 5212167	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Cintins, Marianne M.	
ASSISTANT EXAMINER:	Jordan, Kimberly R.	
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	379	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject application discloses methods for modulating NMDA-mediated
ion transport, and inhibiting non-NMDA glutamate-induced ion transport,
in neuronal cells. The methods involve contacting a neuronal cell with
an effective amount of the neurosteroid pregnenolone sulfate, or
pharmacologically effective derivatives thereof.
IT 148000-91-3
(for central nervous system disorder treatment, methylaspartate receptor in relation to)
RN 148000-91-3 USPATFULL
CN Pregnane-11,20-dione, 3,21-dihydroxy-, mono(hydrogen sulfate), (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

CM 1

CRN 14107-37-0
CMF C21 H32 O4
CDES 4:3A,5A.PREGN

Absolute stereochemistry.

L7 ANSWER 27 OF 65 USPATFULL (Continued)



CM 2

CRN 7664-93-9
CMF H2 O4 S

L7 ANSWER 28 OF 65 USPATFULL
ACCESSION NUMBER: 94:93322 USPATFULL
TITLE: Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
INVENTOR(S): Clark, Abbot F., 5708 Stage Line Dr., Arlington, TX, United States 76017
Southren, Aaron L., 107 Grandview Ave., Monsey, NY, United States 10952

	NUMBER	DATE
PATENT INFORMATION:	US 5358943	19941025
APPLICATION INFO.:	US 1993-12181	19930202 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1989-399349, filed on 28 Aug 1989, now abandoned which is a continuation of Ser. No. US 1987-139227, filed on 29 Dec 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Arno, James A.; Brown, Gregg C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 341
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortisol. The tetrahydrocortisol serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortisol to a patient receiving such therapy.
IT 53-02-1D, Tetrahydrocortisol, mixts. with glucocorticoids
(tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids, and ophthalmic pharmaceuticals contg. combination of tetrahydrocortisol with corticosteroid)
RN 53-02-1 USPATFULL

L7 ANSWER 28 OF 65 USPATFULL (Continued)
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 29 OF 65 USPATFULL
ACCESSION NUMBER: 94:49295 USPATFULL
TITLE: Method for making 3.alpha.-hydroxy, 3.beta.-substituted-pregnanes
INVENTOR(S): Tahir, Hasan, Pasadena, CA, United States
Bolger, Michael, Los Alamitos, CA, United States
Buswell, Richard, Santa Rosa, CA, United States
Gabriel, Richard, Woburn, MA, United States
Stearns, Jay, Santa Rosa, CA, United States
PATENT ASSIGNEE(S): Cocensys Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5319115	19940607
APPLICATION INFO.:	US 1992-846193	19920304 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-745216, filed on 13 Aug 1991, now patented, Pat. No. US 5232917 which is a continuation-in-part of Ser. No. US 1990-521724, filed on 10 May 1990, now patented, Pat. No. US 5120723 which is a continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tsang, Cecilia
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 349
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3.alpha.-hydroxy,3.beta.-substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereoselectively into a 3(R)-pregnan-3-spiro-2'oxirane-20-one intermediate. This intermediate can then be converted regioselectively by a second set of reactions to the 3.alpha.-hydroxy,3.beta.-substituted-20-one form, which can be further modified at the 20-keto position.

Through this method, each ketone group is independently treated. By modifying the ketones one at a time, one can obtain the desired stereo-specificity at each site.
IT 567-02-2
(anticonvulsant and anxiolytic)
RN 567-02-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 29 OF 65 USPATFULL (Continued)

Absolute stereochemistry.



L7 ANSWER 30 OF 65 USPATFULL

ACCESSION NUMBER: 93:63162 USPATFULL
TITLE: Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
INVENTOR(S): Bolger, Michael, Los Alamitos, CA, United States
Gee, Kelvin W., Hacienda Heights, CA, United States
Lan, Nancy C., S. Pasadena, CA, United States
Belelli, Delia, Rowland Heights, CA, United States
Mirsadeghi, Seid, Sherman Oaks, CA, United States
Purdy, Robert, San Antonio, TX, United States
PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5232917	19930803
APPLICATION INFO.:	US 1991-745216	19910813 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-521724, filed on 10 May 1990, now patented, Pat. No. US 5120723 which is a continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tsang, Cecilia
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 119
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 3795
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex.

IT 567-02-2
(anticonvulsant and anxiolytic)
RN 567-02-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 30 OF 65 USPATFULL (Continued)



L7 ANSWER 31 OF 65 USPATFULL

ACCESSION NUMBER: 93:50500 USPATFULL
TITLE: Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies
INVENTOR(S): Ungemach, Frank S., Lake Villa, IL, United States
Nam, Daniel S., Chicago, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5221629	19930622
APPLICATION INFO.:	US 1990-537669	19900614 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1986-866193, filed on 21 May 1986, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Cooperley, Mary E.
LEGAL REPRESENTATIVE: Breininger, Thomas M.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.

IT 53-05-4, Tetrahydrocortisone
(phencyclidine fluorescence polarization immunoassay crossreactivity to)
RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 65 USPATFULL (Continued)



L7 ANSWER 32 OF 65 USPATFULL
ACCESSION NUMBER: 93:39991 USPATFULL
TITLE: Modulation of receptor-mediated ion transport
INVENTOR(S): Farb, David H., Cambridge, MA, United States
PATENT ASSIGNEE(S): Trustees of Boston University, Boston, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5212167	19930518
APPLICATION INFO.:	US 1991-758129	19910912 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Waddell, Frederick E.
ASSISTANT EXAMINER: Jordan, Kimberly
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject application discloses methods for modulating NMDA-mediated ion transport, and inhibiting non-NMDA glutamate-induced ion transport, in neuronal cells. The methods involve contacting a neuronal cell with an effective amount of the neurosteroid pregnenolone sulfate, or pharmacologically effective derivatives thereof.
IT **148000-91-3**
(for central nervous system disorder treatment, methylaspartate receptor in relation to)
RN 148000-91-3 USPATFULL
CN Pregnane-11,20-dione, 3,21-dihydroxy-, mono(hydrogen sulfate), (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

CM 1

CRN 14107-37-0
CMF C21 H32 O4
CDES 4:3A,5A.PREGN

Absolute stereochemistry.

L7 ANSWER 32 OF 65 USPATFULL (Continued)



CM 2

CRN 7664-93-9
CMF H2 O4 S

L7 ANSWER 33 OF 65 USPATFULL
ACCESSION NUMBER: 93:39986 USPATFULL
TITLE: Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
INVENTOR(S): Missel, Paul J. T., Arlington, TX, United States
Lang, John C., Arlington, TX, United States
Jani, Rajni, Fort Worth, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5212162	19930518
APPLICATION INFO.:	US 1992-857673	19920325 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-676146, filed on 27 Mar 1991, now abandoned	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wityshyn, Michael G.
ASSISTANT EXAMINER: Leary, Louise N.
LEGAL REPRESENTATIVE: Cheng, Julie J. L.; Yeager, Sally S.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Ophthalmic compositions comprising combinations of gelling polysaccharides and finely-divided drug carrier substrates which become relatively more viscous on contact with the eye are disclosed. These ophthalmic compositions are both comfortable and long-lasting Ophthalmic compositions further comprising a pharmaceutically active drug are also disclosed, as are methods of use.
IT **53-02-1**, Tetrahydrocortisol
(ophthalmic formulation of, controlled-release)
RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 33 OF 65 USPATFULL (Continued)



L7 ANSWER 34 OF 65 USPATFULL

ACCESSION NUMBER: 93:35677 USPATFULL
TITLE: Method, compositions, and compounds for modulating brain excitability
INVENTOR(S): Gee, Kelvin W., Hacienda Heights, CA, United States
Bolger, Michael B., Los Alamitos, CA, United States
Brinton, Roberta E., New York, NY, United States
Burke, Deborah J., Hacienda Heights, CA, United States
McEwen, Bruce S., Englewood, NJ, United States
PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5208227	19930504
APPLICATION INFO.:	US 1991-655275	19910213 (7)

DISCLAIMER DATE: 20090609
RELATED APPLN. INFO.: Continuation of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tsang, Cecilia
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid/benzodiazepine receptor-chloride ionophore (GBR) complex.

IT 567-02-2
(anticonvulsant and anxiolytic)
RN 567-02-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 34 OF 65 USPATFULL (Continued)



L7 ANSWER 35 OF 65 USPATFULL

ACCESSION NUMBER: 93:6166 USPATFULL
TITLE: Device for assembling superposed, glued web-like layers
INVENTOR(S): Schoch, Gregor, Morges, Switzerland
PATENT ASSIGNEE(S): Bobst SA, Switzerland (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5181330	19930126
APPLICATION INFO.:	US 1991-790592	19911108 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1990-3617	19901114

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Bennet, Henry A.
ASSISTANT EXAMINER: Gromada, Denise L. F.
LEGAL REPRESENTATIVE: Hill, Steadman & Simpson
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 6
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 470
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A device, which assembles web-like workpieces consisting of superimposed glued layers to form a web of corrugated board material, includes three sections with a first section having a single heating plate and an upper blowing case, a second section including upper and lower transverse nozzles, as well as upper and lower suction chambers and a third section including the extension of the upper and lower suction chambers. The device includes a conveying arrangement which has an upper continuous mesh belt passing through the first, second and third sections, and a lower belt passing only through the second and third sections.

IT 53-05-4
(prepn. of cyclodextrin conjugates with drugs to improve water soly.)
RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 35 OF 65 USPATFULL (Continued)



L7 ANSWER 36 OF 65 USPATFULL
ACCESSION NUMBER: 92:84969 USPATFULL
TITLE: Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
INVENTOR(S): Dubler, Robert E., Gurnee, IL, United States
Frintner, Mary P., Elk Grove, IL, United States
Grote, Jonathan, Grayslake, IL, United States
Hadley, Gregg A., St. Louis, MO, United States
Hawksworth, David J., Vernon Hills, IL, United States
Hopkins, Hal D., Chicago, IL, United States
Nam, Daniel S., Lake Elsinore, CA, United States
Ungemach, Frank S., Lake Villa, IL, United States
Wray, Larry K., Highland Park, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5155212	19921013
APPLICATION INFO.:	US 1990-529988	19900529 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-866193, filed on 21 May 1986, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Nucker, Christine
ASSISTANT EXAMINER: Kim, Kay K.
LEGAL REPRESENTATIVE: Breininger, Thomas M.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparting and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.
IT 53-05-4, Tetrahydrocortisone
(phencyclidine fluorescence polarization immunoassay crossreactivity to)
RN 53-05-4 USPATFULL

L7 ANSWER 36 OF 65 USPATFULL (Continued)
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 37 OF 65 USPATFULL
ACCESSION NUMBER: 92:47049 USPATFULL
TITLE: Method, compositions, and compounds for modulating brain excitability
INVENTOR(S): Gee, Kelvin W., Hacienda Heights, CA, United States
Bolger, Michael B., Los Alamitos, CA, United States
PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5120723	19920609
APPLICATION INFO.:	US 1990-521724	19900510 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Shen, Cecilia
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 911
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-ammobutyric acid/benzodiazepine receptor-chloride ionpore (GBR) complex.
IT 567-02-2
(anticonvulsant and anxiolytic)
RN 567-02-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 37 OF 65 USPATFULL (Continued)

L7 ANSWER 38 OF 65 USPATFULL
ACCESSION NUMBER: 91:18943 USPATFULL
TITLE: Tetrahydrocortisol in glaucoma therapy
INVENTOR(S): Southren, Aaron L., Valhalla, NY, United States
Weinstein, Bernard I., Valhalla, NY, United States
Gordon, Gary G., Valhalla, NY, United States
PATENT ASSIGNEE(S): New York Medical College, Valhalla, NY, United States
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4997826	19910305
APPLICATION INFO.:	US 1989-396072	19890821 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1986-864610, filed on 19 May 1986, now patented, Pat. No. US 4863912
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Friedman, Stanley J.
ASSISTANT EXAMINER: Fay, Zohreh A.
LEGAL REPRESENTATIVE: Zarley, McKee, Thomte, Voorhees & Sease
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.
IT 53-02-1, Tetrahydrocortisol
(ophthalmic prepns. contg., for glaucoma treatment)
RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 39 OF 65 USPATFULL
ACCESSION NUMBER: 90:93264 USPATFULL
TITLE: .DELTA..sup.9(11) -angiostatic steroids
INVENTOR(S): Aristoff, Paul A., Portage, MI, United States
Skulnick, Harvey I., Kalamazoo, MI, United States
Wierenga, Wendell, Kalamazoo, MI, United States
PATENT ASSIGNEE(S): The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4975537	19901204
APPLICATION INFO.:	US 1989-351977	19890515 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1987-87228, filed on 19 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1985-790564, filed on 23 Oct 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-811866, filed on 20 Dec 1985, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Ward, Edward C.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 1654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are .DELTA..sup.9(11) -steroids of the formula ##STR1## which have been found to be angiostatic and therefore are useful in the control of embryogenesis, inflammatory conditions, tumor growth as well as other abnormalities.
IT 111245-66-0P 133361-46-3P
(formation of, in prepn. of antiangiogenesis agents)
RN 111245-66-0 USPATFULL
CN Pregn-9(11)-en-20-one, 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 133361-46-3 USPATFULL
CN Pregn-9(11)-en-20-one, 17-(acetyloxy)-6-fluoro-3,21-dihydroxy-16-methyl-, (3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 111245-64-8P 111245-65-9P 111245-67-1P 111245-70-6P 111245-71-7P 133442-74-7P
(prepn. and reaction of, in prepn. of antiangiogenesis agents)
RN 111245-64-8 USPATFULL
CN Pregn-9(11)-en-20-one, 21-(acetyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 111245-65-9 USPATFULL
CN Pregn-9(11)-en-20-one, 21-(acetyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111245-67-1 USPATFULL
CN Pregn-9(11)-en-20-one, 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 111245-70-6 USPATFULL
CN Pregn-9(11)-en-20-one,
21-(acetyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,
(3.beta.,5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111245-71-7 USPATFULL
CN Pregn-9(11)-en-20-one,
21-(acetyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,
(3.alpha.,5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 111320-97-9 USPATFULL
CN Pregn-9(11)-en-20-one, 6-fluoro-3,17,21-trihydroxy-16-methyl-,
(3.alpha.,5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 133442-74-7 USPATFULL
CN Pregn-9(11)-en-20-one,
21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,
(5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 111245-58-0P 111320-97-9P
(prepn. of, as antiangiogenesis agent)
RN 111245-58-0 USPATFULL
CN Pregn-9(11)-en-20-one, 6-fluoro-3,17,21-trihydroxy-16-methyl-,
(3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 40 OF 65 USPATFULL

ACCESSION NUMBER: 90:59474 USPATFULL
TITLE: Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4945089	19900731
APPLICATION INFO.:	US 1989-399351	19890828 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1987-139222, filed on 29 Dec 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Robinson, Douglas W.
ASSISTANT EXAMINER: Fay, Zohreh A.
LEGAL REPRESENTATIVE: Arno, James A.; Brown, Gregg C.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortexolone. The tetrahydrocortexolone serves to substantially prevent any significant increases in intraocular pressure which might otherwise by experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortexolone to a patient receiving such therapy.

IT 68-60-0, Tetrahydrocortexolone
(ophthalmic compn. contg. glucocorticoid and, for intraocular pressure elevation prevention)
RN 68-60-0 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 40 OF 65 USPATFULL (Continued)



L7 ANSWER 41 OF 65 USPATFULL

ACCESSION NUMBER: 89:87537 USPATFULL
TITLE: Methods for controlling ocular hypertension with angiostatic steroids
INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4876250	19891024
APPLICATION INFO.:	US 1988-264918	19881031 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Robinson, Douglas W.
ASSISTANT EXAMINER: Lipovsky, Joseph A.
LEGAL REPRESENTATIVE: Arno, James; Brown, Gregg; Stewart, Sally
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical composition of the angiostatic steroids and methods for their use in treating ocular hypertension, including controlling the ocular hypertension associated with primary open angle glaucoma, are disclosed.
IT 68-60-0, Tetrahydrocortexolone
(glaucoma treatment with)
RN 68-60-0 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 41 OF 65 USPATFULL (Continued)

L7 ANSWER 42 OF 65 USPATFULL

ACCESSION NUMBER: 89:74172 USPATFULL
TITLE: Use of tetrahydrocortisol in glaucoma therapy
INVENTOR(S): Southren, Aaron L., Valhalla, NY, United States
Weinstein, Bernard I., Valhalla, NY, United States
Gordon, Gary G., Valhalla, NY, United States
PATENT ASSIGNEE(S): New York Medical College, Valhalla, NY, United States
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4863912	19890905
APPLICATION INFO.:	US 1986-864610	19860519 (6)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Robinson, Douglas W.
ASSISTANT EXAMINER: Lipovsky, Joseph A.
LEGAL REPRESENTATIVE: Zarley, McKee, Thomte, Voorhees & Sease
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.
IT 53-02-1, Tetrahydrocortisol
(ophthalmic prepns. contg., for glaucoma treatment)
RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 43 OF 65 USPATFULL
ACCESSION NUMBER: 89:27895 USPATFULL
TITLE: Method and composition for arresting angiogenesis and
capillary, cell or membrane leakage
INVENTOR(S): Gillespie, Larrian, Brentwood, CA, United States
PATENT ASSIGNEE(S): Angiogenics, Ltd., San Francisco, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4820693	19890411
APPLICATION INFO.:	US 1987-20859	19870302 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-865981, filed on 22 May 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-848288, filed on 4 Apr 1986, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rollins, John W.
LEGAL REPRESENTATIVE: Sandler & Greenblum
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
LINE COUNT: 698
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition and method for arresting angiogenesis, and cell, capillary or membrane leakage comprising a pharmaceutically effective amount of angiostatic steroid and pentosan polysulfate, or a salt thereof, having the formula: ##STR1## wherein X is at least one member selected from the group consisting of H and --SO.sub.3 Y, and Y is at least one member selected from the group consisting of H and a pharmaceutically acceptable cation.
IT 68-60-0, Tetrahydro S
(pharmaceuticals contg. pentosan polysulfate and, for arresting angiogenesis and capillary, cell or membrane leakage)
RN 68-60-0 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 43 OF 65 USPATFULL (Continued)



L7 ANSWER 44 OF 65 USPATFULL
ACCESSION NUMBER: 88:72350 USPATFULL
TITLE: Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
INVENTOR(S): Kokusho, Yoshitaka, Kunitachi, Japan
Kato, Shigeaki, Hino, Japan
Machida, Haruo, Hino, Japan
PATENT ASSIGNEE(S): Meito Sangyo Kabushiki Kaisha, Aichi, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4783402	19881108
APPLICATION INFO.:	US 1984-598697	19840410 (6)
PRIORITY INFORMATION:	JP 1983-63304	19830411
	JP 1983-63305	19830411

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Hazel, Blondel
LEGAL REPRESENTATIVE: Sherman & Shalloway
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 2054
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing a primary or secondary alcohol derivative of a phospholipid which comprises reacting the phospholipid with a primary or secondary alcohol in the presence of phospholipase DM.
IT 53-02-1 53-05-4
(phosphatidic acid alc. deriv. manuf. from lecithin and, enzymic)
RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-05-4 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA

L7 ANSWER 44 OF 65 USPATFULL (Continued)
INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 45 OF 65 USPATFULL

ACCESSION NUMBER: 88:55514 USPATFULL
TITLE: Antidigoxin antibodies
INVENTOR(S): Lingwood, Clifford A., Toronto, Canada
PATENT ASSIGNEE(S): HSC Research Development Corporation, Toronto, Canada
(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4767720	19880830
APPLICATION INFO.:	US 1985-774370	19850910 (6)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Marantz, Sidney
ASSISTANT EXAMINER: Wagner, Richard
LEGAL REPRESENTATIVE: Banner, Birch, McKie & Beckett
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A digoxin derivative/immunogenic protein conjugate is disclosed which has the carbohydrate moiety of digoxin intact. Antibodies raised against this conjugate show minimal cross-reactivity to digoxin metabolites enabling the use as an antibody in the diagnostic analysis for digoxin when measured in the presence of its metabolites found in serum isolated from a human.

IT **99286-16-5**
(NMR spectrum of)
RN 99286-16-5 USPATFULL
CN Pregnan-20-one,
3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-12,14,21-trihydroxy-, (3.beta.,5.beta.,12.beta.,14.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 65 USPATFULL (Continued)



IT **99286-15-4DP**, immunogenic protein conjugates
(prepn. of and antibodies to, for digoxin immunoassay)
RN 99286-15-4 USPATFULL
CN Pregnan-20-one,
3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-21-[(oxoacetyl)oxy]-, (3.beta.,5.beta.,12.beta.,14.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 45 OF 65 USPATFULL (Continued)

PAGE 1-B

—CHO

IT **99286-15-4P**
(prepn. of, for digoxin immunoassay)
RN 99286-15-4 USPATFULL
CN Pregnan-20-one,
3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-21-[(oxoacetyl)oxy]-, (3.beta.,5.beta.,12.beta.,14.beta.)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CHO

L7 ANSWER 46 OF 65 USPATFULL

ACCESSION NUMBER: 83:27696 USPATFULL
TITLE: Adrenosteriod composition and method for the treatment of shock by infusional therapy
INVENTOR(S): Fussi, Fernando F., Fribourg, Switzerland
PATENT ASSIGNEE(S): Hepar Industries, Franklin, OH, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4391803	19830705
APPLICATION INFO.:	US 1982-375749	19820506 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1982-365867, filed on 5 Apr 1982, now abandoned	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 286
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Septic shock and other forms of shock are effectively treated using a blend of 18 different adrenosteroids in their physiologic ratios based upon an animal cortex extract as a model. The blend preferably administered by infusion to a person suffering from shock. The blend is more effect and at a lower dosage level than hydrocortisone base or water-soluble derivatives of hydrocortisone.

IT **302-91-0 516-16-5 516-45-0 516-47-2 566-02-9**
(infusions of corticosteroid mixts. contg., for septic and traumatic shock treatment)
RN 302-91-0 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 46 OF 65 USPATFULL (Continued)

RN 516-16-5 USPATFULL
CN Pregnan-20-one, 3,11,21-trihydroxy-, (3.beta.,5.alpha.,11.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 516-45-0 USPATFULL
CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.beta.,5.alpha.)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 516-47-2 USPATFULL
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

L7 ANSWER 46 OF 65 USPATFULL (Continued)



RN 566-02-9 USPATFULL
CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 47 OF 65 USPATFULL

ACCESSION NUMBER: 82:36452 USPATFULL
TITLE: Immunochemical assay reagent for the determination of haptens, and assay method therewith
INVENTOR(S): Sakakibara, Kyoichi, Tokyo, Japan
Manita, Hideaki, Sagamihara, Japan
Gondo, Masaaki, Kawasaki, Japan
Yamashita, Haruo, Kunitachi, Japan
PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4341758	19820727
APPLICATION INFO.:	US 1979-83938	19791011 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-125710	19781014
	JP 1978-125711	19781014

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fagelson, Anna P.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1,2,3
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 2279
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel immunochemical assay reagents comprising combinations of (A) a carboxyl-containing water-soluble mono-olefinic polymeric compound combined with a hapten or its chemically modified product, or a hapten-supported latex resulting from the chemical linking of the hapten-bound polymeric compound to a polymeric latex, with (B) a hapten antibody, or a hapten antibody-supported carrier; and a method for immunochemically determining haptens by using the aforesaid reagent. This reagent is very stable and can be stored for an extended period of time without degradation. It enables transition from an agglutination inhibited pattern to an agglutinated pattern to be discerned clearly and rapidly with high sensitivity.

IT 26312-90-3DP, albumin complexes 75088-42-5DP, reduced, reaction products with polyacrylic acid 75088-42-5P
(prepn. of)

RN 26312-90-3 USPATFULL
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11,17,21-trihydroxy-20-oxopregnan-3-yl (9CI) (CA INDEX NAME)

L7 ANSWER 47 OF 65 USPATFULL (Continued)



RN 75088-42-5 USPATFULL
CN L-Lysine, N6-[(phenylmethoxy)carbonyl]-N2-[1-O-[(3.alpha.,5.beta.,11.beta.)-11,17,21-trihydroxypregnan-3-yl]-.beta.-D-glucopyranuronoyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH_2—OH

RN 75088-42-5 USPATFULL
CN L-Lysine, N6-[(phenylmethoxy)carbonyl]-N2-[1-O-[(3.alpha.,5.beta.,11.beta.)-11,17,21-trihydroxypregnan-3-yl]-.beta.-D-glucopyranuronoyl]-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 47 OF 65 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B

—CH_2—OH

L7 ANSWER 48 OF 65 USPATFULL

ACCESSION NUMBER:	81:44727 USPATFULL
TITLE:	Chemical process for fluorinating a tertiary carbon atom in the steroid nucleus
INVENTOR(S):	Barton, Derek H. R., London, England Hesse, Robert H., Cambridge, MA, United States
PATENT ASSIGNEE(S):	Research Institute for Medicine and Chemistry, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4284558	19810818
APPLICATION INFO.:	US 1977-775879	19770309 (5)
DISCLAIMER DATE:	19940719	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1975-581283, filed on 27 May 1975, now patented, Pat. No. US 4036864, issued on 19 Jul 1977	
PRIORITY INFORMATION:	GB 1974-24734	19740604

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Bacon & Thomas
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
LINE COUNT:	1297

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Saturated organic compounds containing a hydrogen atom bound to a tertiary carbon atom may be electrophilically fluorinated by reaction with an electrophilic fluorinating agent such as molecular fluorine or trifluoromethyl hypofluorite under conditions whereby the formation of free fluorine radicals is suppressed, e.g. by the presence of a free radical inhibitor such as oxygen or nitrobenzene, the reactants being substantially homogeneously dispersed in a liquid medium, e.g. a solvent medium such as fluorotrichloromethane or chloroform/fluorotrichlorometha ne, so that the said hydrogen atom is electrophilically replaced by a fluorine atom. The fluorination is highly selective and, in the case of complex substrates such as saturated steroids which contain a number of tertiary C--H bonds, may be substantially completely confined to replacement of the hydrogen atom at the tertiary carbon atom which has

L7 ANSWER 48 OF 65 USPATFULL (Continued)

the highest electron density about the C--H bond. The electron density and thus the direction of the fluorination may be controlled by appropriate selection of substituent groupings in the substrate molecule.

Novel 14.alpha.-fluorosteroids are also disclosed, including compounds having valuable androgenic or progestational activity and useful synthetic intermediates.

IT **58652-60-1**
(fluorination of)

RN 58652-60-1 USPATFULL

CN Pregnan-20-one, 3,21-bis(acetyloxy)-16-methyl-17-(nitrooxy)-, (3.beta.,5.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 49 OF 65 USPATFULL

ACCESSION NUMBER:	81:10709 USPATFULL
TITLE:	Steroid conversion method and products produced thereby
INVENTOR(S):	Breslow, Ronald C. D., Englewood, NJ, United States Corcoran, Richard J., Maywood, NJ, United States Snider, Barry B., Princeton, NJ, United States
PATENT ASSIGNEE(S):	Research Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4252719	19810224
APPLICATION INFO.:	US 1978-934314	19780817 (5)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1977-786060, filed on 8 Apr 1977, now abandoned which is a continuation of Ser. No. US 1975-621163, filed on 9 Oct 1975, now abandoned	

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Cooper, Dunham, Clark, Griffin & Moran
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1,21
NUMBER OF DRAWINGS:	31 Drawing Page(s)
LINE COUNT:	964

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for the removal of selected tertiary hydrogen atoms from 5 .alpha.-steroids of the cholestane, androstane and pregnane series by chlorination of 5 .alpha.-steroids esterified with selected iodoaryl substituted esterifying agents which direct a chlorine atom from the chlorinating agent into reactive proximity to the hydrogen atom to be removed.

IT **77546-98-6P**
(prepn. of)

RN 77546-98-6 USPATFULL

CN Pregn-9(11)-en-20-one, 3-(acetyloxy)-17,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 49 OF 65 USPATFULL (Continued)

L7 ANSWER 50 OF 65 USPATFULL

ACCESSION NUMBER:	80:12729 USPATFULL
TITLE:	Chemical compounds
INVENTOR(S):	Phillipps, Gordon H., Wembley, England May, Peter J., North Harrow, England Ayres, Barry E., Ickenham, England
PATENT ASSIGNEE(S):	Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4192871	19800311
APPLICATION INFO.:	US 1978-907915	19780522 (5)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1976-752513, filed on 20 Dec 1976, now abandoned	
PRIORITY INFORMATION:	GB 1976-357	19760106

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Bacon & Thomas
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1,16,21
LINE COUNT:	2797

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pregnanes and androstanes are described which essentially possess a 3.alpha.-hydroxy group, a 5.alpha.-hydrogen atom or a 4.5- or 5,6-double bond, a 17.alpha.-hydrogen atom and an 11.beta.-aminoester group. Other optional substituents or double bonds may be present. The compounds have anaesthetic activity.

IT 64510-35-6
(hydrolysis of)

RN 64510-35-6 USPATFULL

CN Glycine, N,N-dipropyl-, (3.alpha.,5.alpha.,11.beta.)-21-(acetyloxy)-3-hydroxy-20-oxopregnan-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 50 OF 65 USPATFULL (Continued)



IT 64510-35-6P 64510-36-7P 64510-56-1P 64565-05-5P 64565-95-3P
(prepn. of)

RN 64510-35-6 USPATFULL

CN Glycine, N,N-dipropyl-, (3.alpha.,5.alpha.,11.beta.)-21-(acetyloxy)-3-hydroxy-20-oxopregnan-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 64510-36-7 USPATFULL

CN Glycine, N,N-dipropyl-, (3.alpha.,5.alpha.,11.beta.)-3,21-dihydroxy-20-oxopregnan-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 50 OF 65 USPATFULL (Continued)



RN 64510-56-1 USPATFULL

CN Pregnan-20-one, 3,11-dihydroxy-21-methoxy-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 64565-05-5 USPATFULL

CN Glycine, N,N-diethyl-, (3.alpha.,5.alpha.,11.beta.)-3-hydroxy-21-methoxy-20-oxopregnan-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 50 OF 65 USPATFULL (Continued)

RN 64565-95-3 USPATFULL
CN Pregnan-20-one, 11-[(chloroacetyl)oxy]-3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 51 OF 65 USPATFULL

ACCESSION NUMBER: 77:37370 USPATFULL
TITLE: Chemical process
INVENTOR(S): Barton, Derek Harold Richard, London, England
Hesse, Robert Henry, Cambridge, MA, United States
PATENT ASSIGNEE(S): Research Institute for Medicine and Chemistry Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4036864	19770719
APPLICATION INFO.:	US 1975-581283	19750527 (5)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1,22
LINE COUNT: 1426
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Saturated organic compounds containing a hydrogen atom bound to a tertiary carbon atom may be electrophilically fluorinated by reaction with an electrophilic fluorinating agent such as molecular fluorine or trifluoromethyl hypofluorite under conditions whereby the formation of free fluorine radicals is suppressed, e.g. by the presence of a free radical inhibitor such as oxygen or nitrobenzene, the reactants being substantially homogeneously dispersed in a liquid medium, e.g. a solvent medium such as fluorotrichloromethane or chloroform/fluorotrichlorometha ne, so that the said hydrogen atom is electrophilically replaced by a fluorine atom. The fluoroination is highly selective and, in the case of complex substrates such as saturated steroids which contain a number of tertiary C--H bonds, may be substantially completely confined to replacement of the hydrogen atom at the tertiary carbon atom which has the highest electron density about the C--H bond. The electron density and thus the direction of the fluorination may be controlled by appropriate selection of substituent groupings in the substrate molecule.

Novel 14.alpha.-fluorosteroids are also disclosed, including compounds having valuable androgenic or progestational activity and useful synthetic intermediates.

IT 58652-60-1

L7 ANSWER 51 OF 65 USPATFULL (Continued)
(fluorination of)
RN 58652-60-1 USPATFULL
CN Pregnan-20-one, 3,21-bis(acetyloxy)-16-methyl-17-(nitrooxy)-, (3.beta.,5.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 61841-77-8P
(prepn. of)
RN 61841-77-8 USPATFULL
CN Pregnan-20-one, 3,21-bis(acetyloxy)-9-fluoro-16-methyl-17-(nitrooxy)-, (3.beta.,5.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 52 OF 65 USPATFULL

ACCESSION NUMBER: 77:11539 USPATFULL
TITLE: 22-Cyano-24-norcholanes
INVENTOR(S): Abraham, Nedumparambil A., Dollard des Ormeaux, Canada
Lefebvre, Yvon, Pierrefonds, Canada
PATENT ASSIGNEE(S): American Home Products Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4011212	19770308
APPLICATION INFO.:	US 1975-641128	19751215 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1974-469269, filed on 13 May 1974, now patented, Pat. No. US 3944541	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Venetianer, Stephen
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed herein the 3.beta.,14-dihydroxy-, 3.beta.,5,14-trihydroxy-, 3.beta.,12.beta.,14-trihydroxy- and 3.beta.,14,16.beta.-trihydroxy-21,23-epoxy-23-methoxy-24-nor-5.beta.,14.beta.-chola-20,22-diene-22-carbonitriles, as well as their corresponding 3-acetates, 3-propionates and 3-butyrates and their 3-digitosides and 3.beta.-cyamarosyl-glucosides as encountered in naturally-occuring starting materials. The compounds possess useful cardiotonic activity. Also included are the corresponding 22-cyano-5.beta.-card-20(22)-enolides, useful as intermediates in the preparation of the compounds of this invention and also as cardiotonic agents.

IT 24533-02-6P 59445-44-2P
(prepn. and cyclocondensation of, with ethyl cyanoacetate)
RN 24533-02-6 USPATFULL
CN Pregnan-20-one, 3-(acetyloxy)-14,21-dihydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 52 OF 65 USPATFULL (Continued)



RN 59445-44-2 USPATFULL
CN Pregnan-20-one,
3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-
O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-
.beta.-D-ribo-hexopyranosyl)oxy]-14,21-dihydroxy-,
(3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)



IT 42516-41-6P
(prepn. and selective hydrolysis of)
RN 42516-41-6 USPATFULL
CN Pregnan-20-one, 3-(acetyloxy)-14-hydroxy-21-[(oxoacetyl)oxy]-,
(3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 52 OF 65 USPATFULL (Continued)



L7 ANSWER 53 OF 65 USPATFULL

ACCESSION NUMBER: 76:39285 USPATFULL
TITLE: 20.beta.,21-Epoxy-3.alpha.-hydroxy-5.alpha.-pregnanes and derivatives thereof
INVENTOR(S): Phillipps, Gordon Hanley, Wembley, England
Newall, Christopher Earle, London, England
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3969345	19760713
APPLICATION INFO.:	US 1975-551315	19750220 (5)

RELATED APPLN. INFO.: Division of Ser. No. US 1971-208961, filed on 16 Dec 1971, now patented, Pat. No. US 3882151

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-60065	19701217

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides 3.alpha.-oxygenated pregnane 21-ethers possessing a hydroxy group in the 3.alpha.-position; a hydrogen atom or a methyl group at the 10-position; a hydrogen atom in the 17.alpha.-position; a keto group in the 20-position; and an etherified hydroxyl group in the 21-position.
IT 32354-01-1P 38601-17-1P 38601-29-5P
38601-30-8P 38601-31-9P 38601-32-0P
38601-33-1P 38601-34-2P 38601-35-3P
38601-36-4P 38601-37-5P 38601-38-6P
38601-39-7P 38601-40-0P 38601-41-1P
38601-43-3P 38601-44-4P 38601-45-5P
38601-46-6P 38601-47-7P 38601-48-8P
38746-02-0P
(prepn. of)
RN 32354-01-1 USPATFULL
CN Pregnane-11,20-dione, 21-hydroxy-3-(nitrooxy)-, (3.alpha.,5.alpha.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-17-1 USPATFULL
CN Pregnane-11,20-dione, 21-methoxy-3-(nitrooxy)-, (3.alpha.,5.alpha.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 38601-29-5 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 53 OF 65 USPATFULL (Continued)

RN 38601-30-8 USPATFULL
CN Pregnane-11,20-dione, 21-ethoxy-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-31-9 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-propoxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-32-0 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-(1-methylethoxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-33-1 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-methoxyethoxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-34-2 USPATFULL
CN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-35-3 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-16-methyl-, (3.alpha.,5.alpha.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-36-4 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 53 OF 65 USPATFULL (Continued)

RN 38601-37-5 USPATFULL
CN Pregnane-11,20-dione, 3-(acetyloxy)-21-methoxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-38-6 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-2,21-dimethoxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-39-7 USPATFULL
CN Pregnane-11,20-dione, 21-(2-chloroethoxy)-3-(nitrooxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-40-0 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[2-(4-morpholinyl)ethoxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-41-1 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[2-(4-methyl-1-piperazinyl)ethoxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-43-3 USPATFULL
CN Propanenitrile, 3-[[(3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-44-4 USPATFULL
CN Propanoic acid, 3-[[(3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-45-5 USPATFULL
CN Pregnane-11,20-dione, 21-(2-chloroethoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-46-6 USPATFULL
CN Pregnane-11,20-dione, 21-(3-chloropropoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-47-7 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-(phenylmethoxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-48-8 USPATFULL
CN Pregnane-11,20-dione, 21-(cyclopentyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38746-02-0 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 54 OF 65 USPATFULL

ACCESSION NUMBER:	76:29138 USPATFULL
TITLE:	Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position
INVENTOR(S):	Phillipps, Gordon Hanley, Wembley, England Lawrence, Robin, Stoke Poges, England Newall, Christopher Earle, London, England Wright, Michael, Stoke Poges, England
PATENT ASSIGNEE(S):	Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3959260	19760525
APPLICATION INFO.:	US 1974-488989	19740716 (5)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1973-356097, filed on 1 May 1973, now Defensive Publication No.	
PRIORITY INFORMATION:	GB 1972-21145	19720505
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1493	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the compounds possessing a 3.alpha.-hydroxy group, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position the residue of a sulphur nucleophile or a sulphone or sulphoxide grouping.

IT 51086-87-4P 51086-88-5P 51086-89-6P
51086-90-9P 51086-91-0P 51086-92-1P
51086-93-2P 51086-94-3P 51086-95-4P
51086-96-5P 51086-97-6P 51086-98-7P
51086-99-8P 51087-00-4P 51087-09-3P
51087-10-6P 51087-11-7P 51087-12-8P
51087-13-9P 51087-14-0P 51087-15-1P
51087-17-3P 51087-18-4P 51087-19-5P
51087-20-8P 51087-21-9P 51087-23-1P
51087-25-3P 51087-28-6P 51087-29-7P
51087-30-0P 51087-31-1P 51087-32-2P
51087-33-3P 51087-34-4P 51087-35-5P
51087-36-6P 51087-37-7P 51087-38-8P
51087-39-9P 51087-51-5P 51087-52-6P
(prepn. of)

RN 51086-87-4 USPATFULL
CN Pregnane-11,20-dione, 21-(benzoylthio)-3-hydroxy-, (3.alpha.,5.alpha.)-

L7 ANSWER 54 OF 65 USPATFULL (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-88-5 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-iodobenzoyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-89-6 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-nitrobenzoyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-90-9 USPATFULL
CN Pregnane-11,20-dione, 21-[[2-(ethoxycarbonyl)benzoyl]thio]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-91-0 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-pyridinylcarbonyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-92-1 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-{(3-pyridinylcarbonyl)thio}-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-93-2 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-96-5 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(1-oxobutyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-97-6 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(1-oxopentyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-94-3 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(1-piperidinylacetyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-95-4 USPATFULL
CN Pregnane-11,20-dione, 21-(acetylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-98-7 USPATFULL
CN Pregnan-20-one, 21-(acetylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-99-8 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[[2-(methylthio)benzoyl]thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-00-4 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[[2-(4-morpholinyl)-1-oxopentyl]thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-09-3 USPATFULL
CN Pregnane-11,20-dione, 21-(ethylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-12-8 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(phenylmethyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-13-9 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-thiocyanato-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-14-0 USPATFULL

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-10-6 USPATFULL
CN Pregnane-11,20-dione, 21-(ethylsulfonyl)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-11-7 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(1-methylethyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)
CN Pregnane-11,20-dione, 3-hydroxy-21-[[2-(4-morpholinyl)ethyl]thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-15-1 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[[[2-(4-morpholinyl)ethoxy]thioxomethyl]thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-17-3 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylthioxomethyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-18-4 USPATFULL
CN Pregnane-11,20-dione, 21-(ethylsulfinyl)-3-hydroxy-, [3.alpha.,5.alpha.,21(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-19-5 USPATFULL
CN Pregnane-11,20-dione, 21-(ethylsulfinyl)-3-hydroxy-, [3.alpha.,5.alpha.,21(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-20-8 USPATFULL
CN Pregnane-11,20-dione, 2-ethoxy-3-hydroxy-21-mercapto-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-21-9 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-thiomorpholinylacetyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-23-1 USPATFULL
CN Pregnane-11,20-dione, 21-[[(butylthio)thioxomethyl]thio]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-25-3 USPATFULL
CN Pregnane-11,20-dione, 21-[[(3,6-dihydro-1(2H)-pyridinyl)acetyl]thio]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-28-6 USPATFULL
CN Pregnane-11,20-dione, 21-[(3-chloro-1-oxopropyl)thio]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-29-7 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-30-0 USPATFULL
CN Pregnane-11,20-dione,
3-hydroxy-21-[[3-(4-morpholinyl)-1-oxopropyl]thio]-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-31-1 USPATFULL
CN Pregnane-11,20-dione,
3-hydroxy-21-[[4-(4-morpholinyl)-1-oxobutyl]thio]-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-34-4 USPATFULL
CN Pregnane-11,20-dione, 21-(acetylthio)-3-hydroxy-2-methoxy-,
(2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-35-5 USPATFULL
CN Pregnan-20-one, 21-(acetylthio)-3-hydroxy-2-methoxy-,
(2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-32-2 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-,
(3.alpha.,5.beta.)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-33-3 USPATFULL
CN Pregnane-11,20-dione,
3-hydroxy-2-methyl-21-[(4-morpholinylacetyl)thio]-,
(2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-36-6 USPATFULL
CN Pregnane-11,20-dione,
3-hydroxy-3-methyl-21-[(4-morpholinylacetyl)thio]-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-37-7 USPATFULL
CN 19-Norpregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-38-8 USPATFULL
CN Pregnane-11,20-dione,
2-ethoxy-3-hydroxy-21-[(4-morpholinylacetyl)thio]-,
(2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-39-9 USPATFULL
CN Pregn-1-ene-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-51-5 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-mercapto-, (3.alpha.,5.alpha.)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 51087-52-6 USPATFULL
CN Pregnane-11,20-dione, 21-[(4-chloro-1-oxobutyl)thio]-3-hydroxy-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 55 OF 65 USPATFULL

ACCESSION NUMBER:	76:21864 USPATFULL
TITLE:	Anaesthetic composition containing a steroid of the 5.alpha.-pregnane series and method of using same
INVENTOR(S):	Phillipps, Gordon Hanley, Wembley, England Newall, Christopher Earle, Acton, England Ayres, Barry Edward, Amersham, England
PATENT ASSIGNEE(S):	Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3952031	19760420
APPLICATION INFO.:	US 1974-532612	19741213 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1971-197915, filed on 11 Nov 1971, now patented, Pat. No. US 3869451	
PRIORITY INFORMATION:	GB 1970-53911	19701112

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Bacon & Thomas
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
LINE COUNT:	1788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to steroids of the pregnane and 19-norpregnane series having anaesthetic properties and compositions containing them.

More particularly the present invention relates to such steroids having a variety of substituents in the 2.beta.-position, a 3.alpha.-hydroxy group and a 5.alpha.-hydrogen atom and esters and 20-ketals thereof. At the 11-position of such steroids is preferably either two hydrogen atoms or an oxo group. The compounds according to the invention may conveniently be prepared by reaction of an appropriate 2.alpha.,3.alpha.-epoxy-pregnane or 19-norpregnane with a reagent which introduces the desired 2.beta.-substituent and various modifications of the compound produced are described to produce compounds within the scope of the invention. The present invention provides compositions containing certain steroids of the pregnane and 19-norpregnane series and such compositions generally may be administered intravenously to induce anaesthesia, the invention providing methods of inducing anaesthesia.

IT 38689-90-6P
(prepn. of)

RN 38689-90-6 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-2-methoxy-,

L7 ANSWER 55 OF 65 USPATFULL (Continued)
(2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 56 OF 65 USPATFULL
ACCESSION NUMBER: 76:14331 USPATFULL
TITLE: 22-Cyano-24-norcholanes
INVENTOR(S): Abraham, Nedumparambil A., Dollard des Ormeaux, Canada
Lefebvre, Yvon, Pierrefonds, Canada
PATENT ASSIGNEE(S): American Home Products Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3944541	19760316
APPLICATION INFO.:	US 1974-469269	19740513 (5)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Brown, Johnnie R.
ASSISTANT EXAMINER: Owens, Cary B.
LEGAL REPRESENTATIVE: Floyd, John P.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are disclosed herein the 3.beta., 14-dihydroxy-,3.beta.,5,14-trihydroxy-, 3.beta.,12.beta.,14-trihydroxy- and 3.beta.,14,16.beta.-

trihydroxy-21,23-epoxy-23-methoxy-24-nor-5.beta.,14.beta.-chola-20,22-diene-22-carbonitriles, as well as their corresponding 3-acetates, 3-propionates and 3-butyrates and their 3-digitosides and 3.beta.-cyamarosyl-glucosides as encountered in naturally-occuring starting materials. The compounds possess useful cardiotonic activity.

Also included are the corresponding 22-cyano-5.beta.-card-20(22)-enolides, useful as intermediates in the preparation of the compounds of this invention and also as cardiotonic agents.

IT 3946-61-0P 59445-44-2P
(prepn. and condensation of, with ethyl cyanoacetate)
RN 3946-61-0 USPATFULL
CN Pregnan-20-one, 3,14,21-trihydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 56 OF 65 USPATFULL (Continued)



RN 59445-44-2 USPATFULL
CN Pregnan-20-one, 3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-14,21-dihydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)



IT 59445-48-6P
(prepn. and hydrolysis of)
RN 59445-48-6 USPATFULL
CN Pregnan-20-one, 3,14-dihydroxy-21-[(oxoacetyl)oxy]-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 56 OF 65 USPATFULL (Continued)



L7 ANSWER 57 OF 65 USPATFULL
ACCESSION NUMBER: 76:8956 USPATFULL
TITLE: 15.alpha.,-Sulfonyloxy-12.beta.-hydroxypregnanes and
process for the preparation thereof
INVENTOR(S): Lehmann, Hans-Gunter, Berlin, Germany, Federal Republic
of
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin & Bergkamen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3939187	19760217
APPLICATION INFO.:	US 1974-485062	19740702 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1973-2334559	19730704

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Millen, Raptes & White
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 15.alpha.-Sulfonyl-12.beta.-hydroxypregnanes of the formula ##SPC1## Wherein Ac is lower-acyl and R is alkyl, cycloalkyl, aralkyl or aryl, which are useful as intermediates for the production of digoxigenin, are produced by the selective sulfonic acid esterification of the corresponding 12.beta., 15.alpha.-dihydroxy steroid.
IT 55534-62-8P
(prepn. and dehydrosulfonation of)
RN 55534-62-8 USPATFULL
CN Pregnan-20-one, 3,12,21-tris(acetyloxy)-15-[[(2,4,6-trimethylphenyl)sulfonyl]oxy]-, (3.beta.,5.beta.,12.beta.,15.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 57 OF 65 USPATFULL (Continued)



L7 ANSWER 58 OF 65 USPATFULL
ACCESSION NUMBER: 75:71659 USPATFULL
TITLE: Process for the manufacture of steroid epoxides
INVENTOR(S): Kaufmann, Heinz, Fullinsdorf, Switzerland
Wettstein, Albert, Riehen, Switzerland
PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3929769	19751230
APPLICATION INFO.:	US 1974-451261	19740314 (5)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1973-360230, filed on 14 May 1973, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1972-7479	19720519

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert I.
LEGAL REPRESENTATIVE: Kolodny, Joseph G.; Maitner, John J.; Groeger, Theodore O.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 526
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to a process for the manufacture of 5.alpha.,6.alpha.-oxido-steroids starting from corresponding 5.alpha.,6.beta.-dihydroxy steroids. The starting steroids are treated with a fluorinated amine of the formula ##EQU1## wherein X.sub.1 is chlorine or fluorine, X.sub.2 is chlorine, fluorine or trifluoromethyl and R and R' are alkyl groups or together with the nitrogen atom form a heterocyclic radical. There are preferably used compounds in which R and R' are lower alkyl groups, such as for instance N- (2-chloro-1,1,2-trifluoroethyl)-diethylamine, and the reaction is performed in an inert solvent e.g. ethylene chloride, at room temperature or elevated temperature, if desired, in the presence of another organic nitrogen base. The compounds of the process are intermediates for the preparation of therapeutically useful 6-fluoro-steroids, such as 6-fluoro-corticoids. In particular, the epoxides can be further reacted with the same fluorinated amine used in their preparation to give the 6.beta.,5.alpha.-fluorohydrins.
IT 51467-16-4
(dehydration of, with (chlorotrifluoroethyl)diethylamine)
RN 51467-16-4 USPATFULL
CN Pregnan-20-one, 3,21-bis(acetyloxy)-5,6,17-trihydroxy-, (3.beta.,5.alpha.,6.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 65 USPATFULL (Continued)

Absolute stereochemistry.



L7 ANSWER 59 OF 65 USPATFULL
ACCESSION NUMBER: 75:59665 USPATFULL
TITLE: Steroidal anaesthetic composition for intraveneous injection
INVENTOR(S): Pearce, Derek Roger, Bracknell, England
Davis, Benjamin, Chalfont St. Peter, England
Pearce, Derek Roger, Bracknell, England
Connor, Paul, Chalfont St. Giles, England
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3917830	19751104
APPLICATION INFO.:	US 1972-263133	19720615 (5)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1971-208924, filed on 16 Dec 1971, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-60067	19701217

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition for use by injection as an anaesthetic comprising 3.alpha.-hydroxy 5.alpha.- pregnane - 11,20 dione in solution in an inert organic liquid medium. The composition may be in the form of a solution which also contains water, a non-aqueous solution or an emulsion or microemulsion. The emulsions and microemulsions are preferably of the oil-in-water type.

Water-miscible substances which may be used as or in the liquid medium include polyhydroxy alcohols and water-soluble esters and amides. Other substances which may be used as the liquid medium include oils, long chain alcohols and esters, and fatty acid esters.
IT 23930-37-2
(pharmaceutical solubilizer, for hydroxypregnanedione)
RN 23930-37-2 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 59 OF 65 USPATFULL (Continued)



L7 ANSWER 60 OF 65 USPATFULL
ACCESSION NUMBER: 75:25277 USPATFULL
TITLE: Novel 3.alpha.-hydroxysteroids of the 5.alpha.-pregnane series
INVENTOR(S): Phillipps, Gordon Hanley, Wembley, England
Newall, Christopher Earle, Acton, England
Cook, Martin Christopher, Chalfont St. Peter, England
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, Middlesex, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3883569	19750513
APPLICATION INFO.:	US 1971-208985	19711216 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-60066	19701217

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Steroids of the 5.alpha.-pregnane series possessing a 3.alpha.-hydroxy group, a 10-hydrogen atom or methyl group, an 11-oxo group, a 17.alpha.-hydrogen atom, a 20-oxo group, and a group of the formula -XR at the 21-position wherein -XR represents --OCOR, --OCOOR, --CCOSR or --OCONHR and R represents (a) a solubilising group containing a basic nitrogen atom, (b) a nitrobenzyl group (c) a lower alkyl group (when X is not --OCO--) or (d) a halogenoalkyl group.

The steroids possess anaesthetic properties.
IT 32226-14-5P 32354-01-1P 38392-70-0P
38392-71-1P 38392-72-2P 38392-75-5P
38392-76-6P 38392-77-7P 38392-78-8P
38392-79-9P 38392-80-2P 38392-81-3P
38392-82-4P 38392-85-7P 38392-87-9P
38392-88-0P 38392-89-1P 38392-90-4P
38392-91-5P 38392-92-6P 38392-93-7P
(prepn. of)
RN 32226-14-5 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-3-(nitrooxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 32354-01-1 USPATFULL
CN Pregnane-11,20-dione, 21-hydroxy-3-(nitrooxy)-, (3.alpha.,5.alpha.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 38392-70-0 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[[(4-nitrophenyl)acetyl]oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-71-1 USPATFULL
CN Pregnane-11,20-dione, 21-[[[(4-aminophenyl)acetyl]oxy]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-72-2 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(3-pyridinylcarbonyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-75-5 USPATFULL
CN Pregnane-11,20-dione, 21-[(chloroacetyl)oxy]-3-(nitrooxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-76-6 USPATFULL
CN Pregnane-11,20-dione, 21-[(chloroacetyl)oxy]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-77-7 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(iodoacetyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-78-8 USPATFULL
CN Glycine, N,N-dimethyl-, (3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-79-9 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-80-2 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[[(4-methyl-1-piperazinyl)acetyl]oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-81-3 USPATFULL
CN Pregnane-11,20-dione, 21-[(ethoxycarbonyl)oxy]-3-(nitrooxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-82-4 USPATFULL
CN Pregnane-11,20-dione, 21-[(ethoxycarbonyl)oxy]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-85-7 USPATFULL
CN Glycine, N-[(phenylmethoxy)carbonyl]-, (3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-87-9 USPATFULL
CN Glycine, N,N-diethyl-, (3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-88-0 USPATFULL
CN Glycine, N,N-diethyl-, (2.beta.,3.alpha.,5.alpha.)-3-hydroxy-2-methoxy-11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-89-1 USPATFULL
CN Pregnane-11,20-dione, 21-(acetyloxy)-2-methoxy-3-(nitrooxy)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-90-4 USPATFULL
CN Pregnane-11,20-dione, 21-hydroxy-2-methoxy-3-(nitrooxy)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-91-5 USPATFULL
CN Pregnane-11,20-dione, 21-[(chloroacetyl)oxy]-2-methoxy-3-(nitrooxy)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.